[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$futyVxuIxHd6d3CDiu_QTZ-b7QqPJHkI7GQUW17NjwkU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":85,"rows":92},"Milton S. Hershey Medical Center",[4],484,false,83,36,2781736,314,[13,16,19,22,25,27,30,32],{"name":14,"count":15},"Asthma",20,{"name":17,"count":18},"Breast Cancer",15,{"name":20,"count":21},"Obesity",9,{"name":23,"count":24},"Pain",8,{"name":26,"count":24},"Tobacco Dependence",{"name":28,"count":29},"Endometriosis",7,{"name":31,"count":29},"Autism Spectrum Disorder",{"name":33,"count":29},"Physical Activity",[35,40,45,50,55,60,65,70,75,80],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05239793","Electronic Cigarette-derived Oxidants and Cardiopulmonary Effects","2025-06-30","NJOY e-cigarette",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04802408","SARS-Cov-2 (COVID-19) Nasal Pharyngeal and Oral Pharyngeal Wash (SNOW) Trial","2026-05-30","Shampoo and saline",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT02901821","Predicting Concussion Outcomes With Salivary miRNA","2026-06","salivary RNA collection",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03737292","Liposomal Bupivacaine Versus Plain Bupivacaine After Intercostal Injections For Pain Management After Thoracoscopy","2026-10","Exparel",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT06548490","GLP-1R Agonist Treatment for Opioid Use Disorder","2026-11","Semaglutide Pen Injector",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05301192","Angiotensin-(1-7) Cardiovascular Effects in Aging","2026-12","Angiotensin-",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT05937594","MicroRNA Biomarkers for Neonatal Opioid Withdrawal Syndrome","2026-12-10","Buccal swab saliva for further genetic testing",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT06600698","Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA","2027-05-01","INM176",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT03513770","Autonomic Control of the Circulation and VDR","2027-06-01","ketorolac tromethamine",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT07030933","Amino Acid Infusion in Cardiac Surgery","2027-10-01","Travesol 10%",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,131,170,188,212,238,256,274,292,391,423,456,486,514,544,562,580,607,625,647,665,683,701,719,745,801,823,851,869,887,908,933,957,975,1012,1033,1056,1111,1153,1182,1216,1241,1267,1293,1311,1329,1354,1372,1397,1421,1450,1468,1492,1510,1538,1556,1574,1592,1618,1636,1660,1685,1703,1729,1747,1770,1796,1814,1838,1856,1882,1907,1925,1947,1983,2019,2041,2077,2112,2147,2173,2197,2215,2240,2258,2284,2302,2326,2344,2369,2402,2420,2438,2460,2483,2501,2519,2541,2565,2583,2601,2625,2649,2667,2685,2703,2730,2755,2773,2791,2819,2837,2855,2873,2891,2918,2936,2954,2972,2995,3013,3037,3055,3082,3117,3158,3184,3210,3236,3258,3285,3307,3332,3353,3376,3394,3418,3443,3471,3489,3513,3538,3556,3582,3607,3625,3651,3675,3693,3722,3746,3772,3798,3821,3839,3863,3889,3907,3925,3950,3968,3986,4007,4025,4043,4061,4084,4106,4130,4152,4190,4218,4245,4267,4290,4313,4340,4358,4376,4394,4412,4430,4448,4466,4484,4510,4528,4546,4564,4587,4611,4634,4657,4681,4699,4717,4735,4753,4779,4797,4815,4839,4864,4890,4913,4937,4960,4978,5015,5055,5087,5123,5156,5180,5198,5216,5234,5257,5278,5296,5319,5344,5362,5388,5406,5431,5458,5476,5500,5524,5542,5564,5587,5610,5628,5649,5667,5685,5709,5735,5760,5778,5796,5821,5846,5870,5888,5913,5931,5949,5975,5993],{"intervention":94,"totalTrials":95,"cells":96},"Bupivacaine",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":114,"PHASE3":116,"PHASE4":118,"NA":129},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},"NCT01688596","Injection of Local Anesthetic to Trocar Insertion Sites After Laparoscopy","COMPLETED",[87],"2012-12","2013-01","2012-09",135,[112],"Pain, Postoperative",[94],{"trials":115,"activeCount":99},[],{"trials":117,"activeCount":99},[],{"trials":119,"activeCount":128,"soonestReadout":53},[120],{"nctId":51,"briefTitle":52,"status":121,"phases":122,"primaryCompletion":53,"completion":53,"start":123,"enrollment":124,"conditions":125,"interventions":127},"RECRUITING",[90],"2019-04-09",40,[112,126],"Pharmacokinetics",[54,94],1,{"trials":130,"activeCount":99},[],{"intervention":132,"totalTrials":95,"cells":133},"CNS Stimulant",{"EARLY_PHASE1":134,"PHASE1":136,"PHASE2":138,"PHASE3":140,"PHASE4":142,"NA":168},{"trials":135,"activeCount":99},[],{"trials":137,"activeCount":99},[],{"trials":139,"activeCount":99},[],{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":128,"soonestReadout":159},[144,155],{"nctId":145,"briefTitle":146,"status":147,"phases":148,"primaryCompletion":149,"completion":149,"start":150,"enrollment":151,"conditions":152,"interventions":154},"NCT03279952","Neurophysiological Markers of Pediatric Irritability and Its Response to Intervention","TERMINATED",[90],"2024-06-30","2018-06-01",11,[153],"ADHD",[132],{"nctId":156,"briefTitle":157,"status":121,"phases":158,"primaryCompletion":159,"completion":160,"start":161,"enrollment":162,"conditions":163,"interventions":167},"NCT06871488","Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants",[90],"2030-02-28","2030-06-30","2026-03-05",136,[164,165,166],"ADHD - Attention Deficit Disorder With Hyperactivity","Irritability","Aggression Childhood",[132],{"trials":169,"activeCount":99},[],{"intervention":54,"totalTrials":128,"cells":171},{"EARLY_PHASE1":172,"PHASE1":174,"PHASE2":176,"PHASE3":178,"PHASE4":180,"NA":186},{"trials":173,"activeCount":99},[],{"trials":175,"activeCount":99},[],{"trials":177,"activeCount":99},[],{"trials":179,"activeCount":99},[],{"trials":181,"activeCount":128,"soonestReadout":53},[182],{"nctId":51,"briefTitle":52,"status":121,"phases":183,"primaryCompletion":53,"completion":53,"start":123,"enrollment":124,"conditions":184,"interventions":185},[90],[112,126],[54,94],{"trials":187,"activeCount":99},[],{"intervention":84,"totalTrials":128,"cells":189},{"EARLY_PHASE1":190,"PHASE1":192,"PHASE2":194,"PHASE3":196,"PHASE4":198,"NA":210},{"trials":191,"activeCount":99},[],{"trials":193,"activeCount":99},[],{"trials":195,"activeCount":99},[],{"trials":197,"activeCount":99},[],{"trials":199,"activeCount":128,"soonestReadout":83},[200],{"nctId":81,"briefTitle":82,"status":201,"phases":202,"primaryCompletion":83,"completion":203,"start":204,"enrollment":205,"conditions":206,"interventions":209},"NOT_YET_RECRUITING",[90],"2027-11-01","2026-10-01",130,[207,208],"Acute Kidney Injury","Cardiac Surgery",[84],{"trials":211,"activeCount":99},[],{"intervention":44,"totalTrials":128,"cells":213},{"EARLY_PHASE1":214,"PHASE1":216,"PHASE2":218,"PHASE3":220,"PHASE4":234,"NA":236},{"trials":215,"activeCount":99},[],{"trials":217,"activeCount":99},[],{"trials":219,"activeCount":99},[],{"trials":221,"activeCount":128,"soonestReadout":43},[222],{"nctId":41,"briefTitle":42,"status":223,"phases":224,"primaryCompletion":43,"completion":43,"start":225,"enrollment":226,"conditions":227,"interventions":230},"ACTIVE_NOT_RECRUITING",[88,89],"2021-10-01",171,[228,229],"Covid19","SARS-CoV Infection",[44,231,232,233],"Saline and Listerine","Shampoo and Listerine","Saline and Saline",{"trials":235,"activeCount":99},[],{"trials":237,"activeCount":99},[],{"intervention":231,"totalTrials":128,"cells":239},{"EARLY_PHASE1":240,"PHASE1":242,"PHASE2":244,"PHASE3":246,"PHASE4":252,"NA":254},{"trials":241,"activeCount":99},[],{"trials":243,"activeCount":99},[],{"trials":245,"activeCount":99},[],{"trials":247,"activeCount":128,"soonestReadout":43},[248],{"nctId":41,"briefTitle":42,"status":223,"phases":249,"primaryCompletion":43,"completion":43,"start":225,"enrollment":226,"conditions":250,"interventions":251},[88,89],[228,229],[44,231,232,233],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":99},[],{"intervention":232,"totalTrials":128,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":270,"NA":272},{"trials":259,"activeCount":99},[],{"trials":261,"activeCount":99},[],{"trials":263,"activeCount":99},[],{"trials":265,"activeCount":128,"soonestReadout":43},[266],{"nctId":41,"briefTitle":42,"status":223,"phases":267,"primaryCompletion":43,"completion":43,"start":225,"enrollment":226,"conditions":268,"interventions":269},[88,89],[228,229],[44,231,232,233],{"trials":271,"activeCount":99},[],{"trials":273,"activeCount":99},[],{"intervention":233,"totalTrials":128,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":288,"NA":290},{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":128,"soonestReadout":43},[284],{"nctId":41,"briefTitle":42,"status":223,"phases":285,"primaryCompletion":43,"completion":43,"start":225,"enrollment":226,"conditions":286,"interventions":287},[88,89],[228,229],[44,231,232,233],{"trials":289,"activeCount":99},[],{"trials":291,"activeCount":99},[],{"intervention":293,"totalTrials":294,"cells":295},"Cyclophosphamide",5,{"EARLY_PHASE1":296,"PHASE1":298,"PHASE2":312,"PHASE3":385,"PHASE4":387,"NA":389},{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":99},[300],{"nctId":301,"briefTitle":302,"status":147,"phases":303,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":307,"interventions":309},"NCT00990496","A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)",[87],"2010-10-28","2009-09",25,[308],"Glioblastoma Multiforme",[310,293,311],"Fludarabine","CMV Specific Cytotoxic T Lymphocytes",{"trials":313,"activeCount":95,"soonestReadout":318},[314,327,342,363],{"nctId":315,"briefTitle":316,"status":121,"phases":317,"primaryCompletion":318,"completion":319,"start":320,"enrollment":321,"conditions":322,"interventions":326},"NCT06926595","Allogeneic HSCT With Low-Dose Post-Transplant Cyclophosphamide for GVHD Prevention",[88],"2030-11-01","2031-11-01","2026-03-09",41,[323,324,325],"Graft-versus-Host Disease (GVHD)","Hematologic Malignancies","Allogeneic Stem Cell Transplantation",[293],{"nctId":328,"briefTitle":329,"status":147,"phases":330,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":334,"interventions":336},"NCT04002115","Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML",[88],"2022-08-30","2022-11-07","2020-06-03",[335],"Acute Myeloid Leukemia",[337,310,338,293,339,340,341],"Clofarabine","Busulfan","Granulocyte Colony-Stimulating Factor","Tacrolimus","Cellcept",{"nctId":343,"briefTitle":344,"status":121,"phases":345,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":350,"interventions":354},"NCT07321912","Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma",[88],"2031-04-01","2036-04-01","2026-05-21",406,[351,352,353],"Osteosarcoma","Ewing Sarcoma","Ewing Sarcoma Metastatic",[355,356,293,357,358,359,360,361,362],"Eflornithine","Topotecan","Vincristine","Doxorubicin","Ifosfamide","Etoposide","Cisplatin","Methotrexate",{"nctId":364,"briefTitle":365,"status":366,"phases":367,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":369,"interventions":378},"NCT00084695","Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases","UNKNOWN",[88],"2003-09",[370,371,372,373,374,375,376,377],"Childhood Langerhans Cell Histiocytosis","Fanconi Anemia","Leukemia","Lymphoma","Myelodysplastic Syndromes","Neuroblastoma","Sarcoma","Unspecified Childhood Solid Tumor, Protocol Specific",[379,380,381,382,383,384],"anti-thymocyte globulin","busulfan","cyclophosphamide","fludarabine phosphate","melphalan","methylprednisolone",{"trials":386,"activeCount":99},[],{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":357,"totalTrials":95,"cells":392},{"EARLY_PHASE1":393,"PHASE1":395,"PHASE2":397,"PHASE3":417,"PHASE4":419,"NA":421},{"trials":394,"activeCount":99},[],{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":95,"soonestReadout":318},[399,413],{"nctId":400,"briefTitle":401,"status":121,"phases":402,"primaryCompletion":318,"completion":403,"start":404,"enrollment":405,"conditions":406,"interventions":409},"NCT06541262","Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors",[87,88],"2035-11-01","2024-10-30",104,[375,352,351,407,408],"Rhabdomyosarcoma","Liposarcoma",[410,411,412,357],"Silmitasertib","Irinotecan","Temozolomide",{"nctId":343,"briefTitle":344,"status":121,"phases":414,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":415,"interventions":416},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":418,"activeCount":99},[],{"trials":420,"activeCount":99},[],{"trials":422,"activeCount":99},[],{"intervention":355,"totalTrials":95,"cells":424},{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":450,"PHASE4":452,"NA":454},{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"trials":430,"activeCount":95,"soonestReadout":346},[431,446],{"nctId":432,"briefTitle":433,"status":121,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":439,"interventions":444},"NCT06465199","Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas",[87,88],"2033-02","2035-02","2026-04-28",289,[440,441,352,442,351,375,443],"Atypical Teratoid\u002FRhabdoid Tumor","Embryonal Tumor With Multilayered Rosettes","Diffuse Intrinsic Pontine Glioma","DIPG Brain Tumor",[355,445],"AMXT 1501 Dicaprate",{"nctId":343,"briefTitle":344,"status":121,"phases":447,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":448,"interventions":449},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"intervention":412,"totalTrials":95,"cells":457},{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":480,"PHASE4":482,"NA":484},{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":99},[],{"trials":463,"activeCount":128,"soonestReadout":318},[464,468],{"nctId":400,"briefTitle":401,"status":121,"phases":465,"primaryCompletion":318,"completion":403,"start":404,"enrollment":405,"conditions":466,"interventions":467},[87,88],[375,352,351,407,408],[410,411,412,357],{"nctId":469,"briefTitle":470,"status":105,"phases":471,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":476,"interventions":478},"NCT01124734","High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma",[88],"2017-07-18","2018-07-01","2010-05",17,[477],"Malignant Melanoma",[479,412],"Interleukin-2",{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":99},[],{"trials":485,"activeCount":99},[],{"intervention":360,"totalTrials":95,"cells":487},{"EARLY_PHASE1":488,"PHASE1":490,"PHASE2":502,"PHASE3":508,"PHASE4":510,"NA":512},{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":99},[492],{"nctId":493,"briefTitle":494,"status":147,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":500},"NCT00882076","Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias",[87],"2011-03","2009-03",22,[372],[337,501,360],"Mitoxantrone",{"trials":503,"activeCount":128,"soonestReadout":346},[504],{"nctId":343,"briefTitle":344,"status":121,"phases":505,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":506,"interventions":507},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":99},[],{"intervention":515,"totalTrials":95,"cells":516},"methotrexate",{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":532,"PHASE3":538,"PHASE4":540,"NA":542},{"trials":518,"activeCount":99},[],{"trials":520,"activeCount":99},[521],{"nctId":522,"briefTitle":523,"status":105,"phases":524,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":529,"interventions":530},"NCT00112645","Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors",[87],"2010-04","2011-02","2005-04",10,[375,376,377],[379,380,531,383,515,384],"cyclosporine",{"trials":533,"activeCount":128,"soonestReadout":346},[534],{"nctId":343,"briefTitle":344,"status":121,"phases":535,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":536,"interventions":537},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":539,"activeCount":99},[],{"trials":541,"activeCount":99},[],{"trials":543,"activeCount":99},[],{"intervention":410,"totalTrials":128,"cells":545},{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":556,"PHASE4":558,"NA":560},{"trials":547,"activeCount":99},[],{"trials":549,"activeCount":99},[],{"trials":551,"activeCount":128,"soonestReadout":318},[552],{"nctId":400,"briefTitle":401,"status":121,"phases":553,"primaryCompletion":318,"completion":403,"start":404,"enrollment":405,"conditions":554,"interventions":555},[87,88],[375,352,351,407,408],[410,411,412,357],{"trials":557,"activeCount":99},[],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":99},[],{"intervention":411,"totalTrials":128,"cells":563},{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":574,"PHASE4":576,"NA":578},{"trials":565,"activeCount":99},[],{"trials":567,"activeCount":99},[],{"trials":569,"activeCount":128,"soonestReadout":318},[570],{"nctId":400,"briefTitle":401,"status":121,"phases":571,"primaryCompletion":318,"completion":403,"start":404,"enrollment":405,"conditions":572,"interventions":573},[87,88],[375,352,351,407,408],[410,411,412,357],{"trials":575,"activeCount":99},[],{"trials":577,"activeCount":99},[],{"trials":579,"activeCount":99},[],{"intervention":59,"totalTrials":128,"cells":581},{"EARLY_PHASE1":582,"PHASE1":584,"PHASE2":586,"PHASE3":601,"PHASE4":603,"NA":605},{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":128,"soonestReadout":58},[588],{"nctId":56,"briefTitle":57,"status":121,"phases":589,"primaryCompletion":58,"completion":58,"start":590,"enrollment":591,"conditions":592,"interventions":600},[88],"2025-01-13",200,[593,594,595,596,597,598,599],"Opioid Use Disorder","Opioid Abuse and Addiction","Narcotic-Related Disorders","Substance-Related Disorders","Chemically-Induced Disorders","Mental Disorder","Opioid",[59],{"trials":602,"activeCount":99},[],{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[],{"intervention":445,"totalTrials":128,"cells":608},{"EARLY_PHASE1":609,"PHASE1":611,"PHASE2":613,"PHASE3":619,"PHASE4":621,"NA":623},{"trials":610,"activeCount":99},[],{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":128,"soonestReadout":435},[615],{"nctId":432,"briefTitle":433,"status":121,"phases":616,"primaryCompletion":435,"completion":436,"start":437,"enrollment":438,"conditions":617,"interventions":618},[87,88],[440,441,352,442,351,375,443],[355,445],{"trials":620,"activeCount":99},[],{"trials":622,"activeCount":99},[],{"trials":624,"activeCount":99},[],{"intervention":74,"totalTrials":128,"cells":626},{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":641,"PHASE4":643,"NA":645},{"trials":628,"activeCount":99},[],{"trials":630,"activeCount":99},[],{"trials":632,"activeCount":128,"soonestReadout":73},[633],{"nctId":71,"briefTitle":72,"status":121,"phases":634,"primaryCompletion":73,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":640},[87,88],"2028-05-01","2025-05-07",45,[639],"Prostate Cancer",[74],{"trials":642,"activeCount":99},[],{"trials":644,"activeCount":99},[],{"trials":646,"activeCount":99},[],{"intervention":356,"totalTrials":128,"cells":648},{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":659,"PHASE4":661,"NA":663},{"trials":650,"activeCount":99},[],{"trials":652,"activeCount":99},[],{"trials":654,"activeCount":128,"soonestReadout":346},[655],{"nctId":343,"briefTitle":344,"status":121,"phases":656,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":657,"interventions":658},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":660,"activeCount":99},[],{"trials":662,"activeCount":99},[],{"trials":664,"activeCount":99},[],{"intervention":358,"totalTrials":128,"cells":666},{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":671,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[],{"trials":672,"activeCount":128,"soonestReadout":346},[673],{"nctId":343,"briefTitle":344,"status":121,"phases":674,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":675,"interventions":676},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":678,"activeCount":99},[],{"trials":680,"activeCount":99},[],{"trials":682,"activeCount":99},[],{"intervention":359,"totalTrials":128,"cells":684},{"EARLY_PHASE1":685,"PHASE1":687,"PHASE2":689,"PHASE3":695,"PHASE4":697,"NA":699},{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":128,"soonestReadout":346},[691],{"nctId":343,"briefTitle":344,"status":121,"phases":692,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":693,"interventions":694},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":696,"activeCount":99},[],{"trials":698,"activeCount":99},[],{"trials":700,"activeCount":99},[],{"intervention":361,"totalTrials":128,"cells":702},{"EARLY_PHASE1":703,"PHASE1":705,"PHASE2":707,"PHASE3":713,"PHASE4":715,"NA":717},{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[],{"trials":708,"activeCount":128,"soonestReadout":346},[709],{"nctId":343,"briefTitle":344,"status":121,"phases":710,"primaryCompletion":346,"completion":347,"start":348,"enrollment":349,"conditions":711,"interventions":712},[88],[351,352,353],[355,356,293,357,358,359,360,361,362],{"trials":714,"activeCount":99},[],{"trials":716,"activeCount":99},[],{"trials":718,"activeCount":99},[],{"intervention":720,"totalTrials":128,"cells":721},"CBG\u002FCBD Oil",{"EARLY_PHASE1":722,"PHASE1":724,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":128,"soonestReadout":730},[726],{"nctId":727,"briefTitle":728,"status":121,"phases":729,"primaryCompletion":730,"completion":731,"start":732,"enrollment":733,"conditions":734,"interventions":736},"NCT07016971","CBG\u002FCBD Oil for Chemotherapy-Induced Peripheral Neuropathy",[87],"2029-04-03","2029-07-03","2026-04-03",12,[735],"Chemotherapy-Induced Peripheral Neuropathy",[720],{"trials":738,"activeCount":99},[],{"trials":740,"activeCount":99},[],{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"intervention":746,"totalTrials":747,"cells":748},"Saline",4,{"EARLY_PHASE1":749,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":799},{"trials":750,"activeCount":95,"soonestReadout":63},[751,761,768],{"nctId":752,"briefTitle":753,"status":121,"phases":754,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":758,"interventions":760},"NCT06482853","Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension",[86],"2029-03","2025-01-23",52,[20,759],"Hypertension",[64,746],{"nctId":61,"briefTitle":62,"status":121,"phases":762,"primaryCompletion":63,"completion":63,"start":763,"enrollment":764,"conditions":765,"interventions":767},[86],"2022-12-09",26,[766],"Aging",[64,746],{"nctId":769,"briefTitle":770,"status":147,"phases":771,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":775,"interventions":777},"NCT03240068","Angiotensin-(1-7) in Peripheral Arterial Disease",[86],"2020-03-09","2017-09-01",6,[776],"Peripheral Arterial Disease",[778,746],"Angiotensin 1-7",{"trials":780,"activeCount":99},[],{"trials":782,"activeCount":99},[],{"trials":784,"activeCount":99},[],{"trials":786,"activeCount":99},[787],{"nctId":788,"briefTitle":789,"status":105,"phases":790,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":795,"interventions":797},"NCT03604549","Sonographic Hysterosalpingography: Oil vs Water Based Media (SHOW Trial)",[90],"2021-05-31","2021-08-25","2019-01-11",58,[796],"Infertility",[798,746],"Lipiodol UF",{"trials":800,"activeCount":99},[],{"intervention":64,"totalTrials":95,"cells":802},{"EARLY_PHASE1":803,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":804,"activeCount":95,"soonestReadout":63},[805,809],{"nctId":752,"briefTitle":753,"status":121,"phases":806,"primaryCompletion":755,"completion":755,"start":756,"enrollment":757,"conditions":807,"interventions":808},[86],[20,759],[64,746],{"nctId":61,"briefTitle":62,"status":121,"phases":810,"primaryCompletion":63,"completion":63,"start":763,"enrollment":764,"conditions":811,"interventions":812},[86],[766],[64,746],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"trials":820,"activeCount":99},[],{"trials":822,"activeCount":99},[],{"intervention":824,"totalTrials":128,"cells":825},"Vitamin B6 25 MG",{"EARLY_PHASE1":826,"PHASE1":841,"PHASE2":843,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":827,"activeCount":128,"soonestReadout":832},[828],{"nctId":829,"briefTitle":830,"status":201,"phases":831,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":835,"interventions":838},"NCT06369350","Vitamin B6 on Exercise Pressor Reflex on Leg Ischemia-reperfusion",[86],"2028-09","2027-12",30,[836,837],"Ischemia Reperfusion Injury","Peripheral Artery Disease",[824,839,840],"Vitamin B6 50 MG","Vitamin B6 100 MG",{"trials":842,"activeCount":99},[],{"trials":844,"activeCount":99},[],{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[],{"intervention":839,"totalTrials":128,"cells":852},{"EARLY_PHASE1":853,"PHASE1":859,"PHASE2":861,"PHASE3":863,"PHASE4":865,"NA":867},{"trials":854,"activeCount":128,"soonestReadout":832},[855],{"nctId":829,"briefTitle":830,"status":201,"phases":856,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":857,"interventions":858},[86],[836,837],[824,839,840],{"trials":860,"activeCount":99},[],{"trials":862,"activeCount":99},[],{"trials":864,"activeCount":99},[],{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[],{"intervention":840,"totalTrials":128,"cells":870},{"EARLY_PHASE1":871,"PHASE1":877,"PHASE2":879,"PHASE3":881,"PHASE4":883,"NA":885},{"trials":872,"activeCount":128,"soonestReadout":832},[873],{"nctId":829,"briefTitle":830,"status":201,"phases":874,"primaryCompletion":832,"completion":832,"start":833,"enrollment":834,"conditions":875,"interventions":876},[86],[836,837],[824,839,840],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"trials":882,"activeCount":99},[],{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"intervention":39,"totalTrials":128,"cells":888},{"EARLY_PHASE1":889,"PHASE1":898,"PHASE2":900,"PHASE3":902,"PHASE4":904,"NA":906},{"trials":890,"activeCount":128,"soonestReadout":38},[891],{"nctId":36,"briefTitle":37,"status":223,"phases":892,"primaryCompletion":38,"completion":893,"start":894,"enrollment":834,"conditions":895,"interventions":897},[86],"2026-06-30","2022-11-22",[896],"Chronic Obstructive Pulmonary Disease",[39],{"trials":899,"activeCount":99},[],{"trials":901,"activeCount":99},[],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":99},[],{"trials":907,"activeCount":99},[],{"intervention":909,"totalTrials":128,"cells":910},"Estradiol",{"EARLY_PHASE1":911,"PHASE1":923,"PHASE2":925,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":912,"activeCount":128,"soonestReadout":832},[913],{"nctId":914,"briefTitle":915,"status":201,"phases":916,"primaryCompletion":832,"completion":917,"start":918,"enrollment":15,"conditions":919,"interventions":922},"NCT06369363","Estrogen Deficiency on Cardiovascular Risk",[86],"2028-11","2026-09",[920,921],"Postmenopausal Symptoms","Cardiovascular Diseases",[909],{"trials":924,"activeCount":99},[],{"trials":926,"activeCount":99},[],{"trials":928,"activeCount":99},[],{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"intervention":79,"totalTrials":128,"cells":934},{"EARLY_PHASE1":935,"PHASE1":947,"PHASE2":949,"PHASE3":951,"PHASE4":953,"NA":955},{"trials":936,"activeCount":128,"soonestReadout":78},[937],{"nctId":76,"briefTitle":77,"status":121,"phases":938,"primaryCompletion":78,"completion":939,"start":940,"enrollment":941,"conditions":942,"interventions":945},[86],"2027-08-31","2019-08-14",18,[943,944],"Venous Distension Reflex","Blood Pressure",[79,946],"saline control",{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":99},[],{"trials":956,"activeCount":99},[],{"intervention":946,"totalTrials":128,"cells":958},{"EARLY_PHASE1":959,"PHASE1":965,"PHASE2":967,"PHASE3":969,"PHASE4":971,"NA":973},{"trials":960,"activeCount":128,"soonestReadout":78},[961],{"nctId":76,"briefTitle":77,"status":121,"phases":962,"primaryCompletion":78,"completion":939,"start":940,"enrollment":941,"conditions":963,"interventions":964},[86],[943,944],[79,946],{"trials":966,"activeCount":99},[],{"trials":968,"activeCount":99},[],{"trials":970,"activeCount":99},[],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"intervention":976,"totalTrials":95,"cells":977},"Trazodone",{"EARLY_PHASE1":978,"PHASE1":994,"PHASE2":996,"PHASE3":998,"PHASE4":1000,"NA":1002},{"trials":979,"activeCount":128,"soonestReadout":984},[980],{"nctId":981,"briefTitle":982,"status":121,"phases":983,"primaryCompletion":984,"completion":985,"start":986,"enrollment":987,"conditions":988,"interventions":993},"NCT06281756","Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia",[86],"2027-11-30","2028-05-31","2024-03-20",600,[989,990,991,944,992],"Insomnia","Insomnia Chronic","Insomnia, Primary","Blood Pressure, High",[976],{"trials":995,"activeCount":99},[],{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[1004],{"nctId":1005,"briefTitle":1006,"status":105,"phases":1007,"primaryCompletion":150,"completion":150,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1011},"NCT01348542","Study of Trazodone & Cognitive Behavioral Therapy to Treat Insomnia",[91],"2011-04",24,[989],[976],{"intervention":49,"totalTrials":128,"cells":1013},{"EARLY_PHASE1":1014,"PHASE1":1016,"PHASE2":1018,"PHASE3":1020,"PHASE4":1022,"NA":1024},{"trials":1015,"activeCount":99},[],{"trials":1017,"activeCount":99},[],{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":99},[],{"trials":1025,"activeCount":128,"soonestReadout":48},[1026],{"nctId":46,"briefTitle":47,"status":223,"phases":1027,"primaryCompletion":48,"completion":48,"start":1028,"enrollment":1029,"conditions":1030,"interventions":1032},[],"2016-01",700,[1031],"Concussion, Mild",[49],{"intervention":69,"totalTrials":128,"cells":1034},{"EARLY_PHASE1":1035,"PHASE1":1037,"PHASE2":1039,"PHASE3":1041,"PHASE4":1043,"NA":1045},{"trials":1036,"activeCount":99},[],{"trials":1038,"activeCount":99},[],{"trials":1040,"activeCount":99},[],{"trials":1042,"activeCount":99},[],{"trials":1044,"activeCount":99},[],{"trials":1046,"activeCount":128,"soonestReadout":68},[1047],{"nctId":66,"briefTitle":67,"status":121,"phases":1048,"primaryCompletion":68,"completion":1049,"start":1050,"enrollment":1051,"conditions":1052,"interventions":1055},[],"2027-04-10","2020-01-15",50,[1053,1054],"Neonatal Opioid Withdrawal Syndrome","Neonatal Abstinence Syndrome",[69],{"intervention":1057,"totalTrials":1058,"cells":1059},"Normal saline",3,{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1079,"PHASE4":1094,"NA":1109},{"trials":1061,"activeCount":99},[],{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[1066],{"nctId":1067,"briefTitle":1068,"status":105,"phases":1069,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1075},"NCT01475331","The CHARM Trial: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts",[88],"2017-01","2011-11",46,[1074],"Mucinous Pancreatic Cysts",[1076,1077,1078],"Ethanol","Normal Saline","Chemotherapy",{"trials":1080,"activeCount":99},[1081],{"nctId":1082,"briefTitle":1083,"status":147,"phases":1084,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1089,"interventions":1092},"NCT03085004","CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts",[89],"2025-12-31","2026-02-01","2019-04-12",75,[1090,1091],"Pancreatic Cyst","EUS-FNA",[1076,1057,1093],"Paclitaxel + Gemcitabine admixture",{"trials":1095,"activeCount":99},[1096],{"nctId":1097,"briefTitle":1098,"status":147,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":15,"conditions":1103,"interventions":1107},"NCT03691935","Erector Spinae Plane Block (ESPB): in Patients Undergoing Surgery Through a Flank or Anterior Subcostal Incision.",[90],"2024-01-19","2024-02-02","2018-09-28",[1104,1105,1106],"Nephrectomy","Partial Nephrectomy","Incision Site Discomfort",[1108,1057],"Ropivacaine",{"trials":1110,"activeCount":99},[],{"intervention":1108,"totalTrials":1058,"cells":1112},{"EARLY_PHASE1":1113,"PHASE1":1115,"PHASE2":1130,"PHASE3":1132,"PHASE4":1134,"NA":1151},{"trials":1114,"activeCount":99},[],{"trials":1116,"activeCount":99},[1117],{"nctId":1118,"briefTitle":1119,"status":1120,"phases":1121,"primaryCompletion":1122,"completion":1122,"start":1123,"enrollment":99,"conditions":1124,"interventions":1129},"NCT06925789","Influence of Standardized Perioperative Anesthetic, Analgesic Care on Outcome of Patients Undergoing Hip Fracture Surgeries","WITHDRAWN",[87],"2026-05-01","2025-07-01",[1125,1126,1127,1128],"Fractures, Hip","Local Anesthesia","Geriatric","Nerve Block",[1108],{"trials":1131,"activeCount":99},[],{"trials":1133,"activeCount":99},[],{"trials":1135,"activeCount":99},[1136,1147],{"nctId":1137,"briefTitle":1138,"status":105,"phases":1139,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":733,"conditions":1143,"interventions":1145},"NCT03476642","Distribution, Pharmacokinetics and Extent of Sensory Blockade in ESP Blocks",[90],"2024-02-19","2024-03-31","2019-07-02",[1144],"Distribution of Ropivacaine in Erector Spinae Plane Block",[1108,1146],"Epinephrine",{"nctId":1097,"briefTitle":1098,"status":147,"phases":1148,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":15,"conditions":1149,"interventions":1150},[90],[1104,1105,1106],[1108,1057],{"trials":1152,"activeCount":99},[],{"intervention":1146,"totalTrials":95,"cells":1154},{"EARLY_PHASE1":1155,"PHASE1":1157,"PHASE2":1159,"PHASE3":1161,"PHASE4":1163,"NA":1180},{"trials":1156,"activeCount":99},[],{"trials":1158,"activeCount":99},[],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[1165,1169],{"nctId":1137,"briefTitle":1138,"status":105,"phases":1166,"primaryCompletion":1140,"completion":1141,"start":1142,"enrollment":733,"conditions":1167,"interventions":1168},[90],[1144],[1108,1146],{"nctId":1170,"briefTitle":1171,"status":147,"phases":1172,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1176,"interventions":1178},"NCT02895035","Comparison of Epinephrine and Phenylephrine\u002FKetorolac With Regards to Pupil Size",[90],"2018-12-31","2016-09-01",59,[1177],"Cataract",[1179,1146],"Phenylephrine-ketorolac",{"trials":1181,"activeCount":99},[],{"intervention":1183,"totalTrials":95,"cells":1184},"Lumason",{"EARLY_PHASE1":1185,"PHASE1":1197,"PHASE2":1199,"PHASE3":1201,"PHASE4":1203,"NA":1214},{"trials":1186,"activeCount":99},[1187],{"nctId":1188,"briefTitle":1189,"status":1120,"phases":1190,"primaryCompletion":1191,"completion":1192,"start":1193,"enrollment":99,"conditions":1194,"interventions":1196},"NCT05957042","Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI).",[86],"2026-09-01","2031-09-01","2023-09-01",[17,1195],"Contrast Enhanced Ultrasound",[1183],{"trials":1198,"activeCount":99},[],{"trials":1200,"activeCount":99},[],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[1205],{"nctId":1206,"briefTitle":1207,"status":105,"phases":1208,"primaryCompletion":1209,"completion":1209,"start":1210,"enrollment":764,"conditions":1211,"interventions":1213},"NCT04569799","Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE",[90],"2022-10-11","2020-10-14",[1212],"Hepatocellular Carcinoma",[1183],{"trials":1215,"activeCount":99},[],{"intervention":1217,"totalTrials":128,"cells":1218},"Triamcinolone",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1227,"NA":1239},{"trials":1220,"activeCount":99},[],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"trials":1226,"activeCount":99},[],{"trials":1228,"activeCount":99},[1229],{"nctId":1230,"briefTitle":1231,"status":147,"phases":1232,"primaryCompletion":1233,"completion":1233,"start":1234,"enrollment":1235,"conditions":1236,"interventions":1238},"NCT03586687","Osteoarthritis Shoulder Injection Study",[90],"2021-09-28","2018-07-13",19,[1237],"Glenohumeral Osteoarthritis",[1217],{"trials":1240,"activeCount":99},[],{"intervention":1242,"totalTrials":128,"cells":1243},"Misoprostol",{"EARLY_PHASE1":1244,"PHASE1":1246,"PHASE2":1248,"PHASE3":1250,"PHASE4":1252,"NA":1265},{"trials":1245,"activeCount":99},[],{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[1254],{"nctId":1255,"briefTitle":1256,"status":147,"phases":1257,"primaryCompletion":1258,"completion":1258,"start":1259,"enrollment":1260,"conditions":1261,"interventions":1264},"NCT02777190","A Comparison of Oral Misoprostol and Vaginal Misoprostol for Cervical Ripening and Induction of Labor",[90],"2019-04-23","2017-11-01",34,[1262,1263],"Labor; Forced or Induced, Affecting Fetus or Newborn","Pregnancy",[1242],{"trials":1266,"activeCount":99},[],{"intervention":1268,"totalTrials":128,"cells":1269},"2% Lidocaine HCl topical solution",{"EARLY_PHASE1":1270,"PHASE1":1272,"PHASE2":1274,"PHASE3":1276,"PHASE4":1278,"NA":1291},{"trials":1271,"activeCount":99},[],{"trials":1273,"activeCount":99},[],{"trials":1275,"activeCount":99},[],{"trials":1277,"activeCount":99},[],{"trials":1279,"activeCount":99},[1280],{"nctId":1281,"briefTitle":1282,"status":1120,"phases":1283,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":99,"conditions":1287,"interventions":1289},"NCT04810494","Intranasal Lidocaine for Prevention of Postoperative Nausea and Vomiting.",[90],"2023-03-31","2023-06-30","2022-10-01",[1288],"Postoperative Nausea and Vomiting",[1268,1290],"0.9% Sodium chloride",{"trials":1292,"activeCount":99},[],{"intervention":1290,"totalTrials":128,"cells":1294},{"EARLY_PHASE1":1295,"PHASE1":1297,"PHASE2":1299,"PHASE3":1301,"PHASE4":1303,"NA":1309},{"trials":1296,"activeCount":99},[],{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[],{"trials":1302,"activeCount":99},[],{"trials":1304,"activeCount":99},[1305],{"nctId":1281,"briefTitle":1282,"status":1120,"phases":1306,"primaryCompletion":1284,"completion":1285,"start":1286,"enrollment":99,"conditions":1307,"interventions":1308},[90],[1288],[1268,1290],{"trials":1310,"activeCount":99},[],{"intervention":798,"totalTrials":128,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1317,"PHASE3":1319,"PHASE4":1321,"NA":1327},{"trials":1314,"activeCount":99},[],{"trials":1316,"activeCount":99},[],{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"trials":1322,"activeCount":99},[1323],{"nctId":788,"briefTitle":789,"status":105,"phases":1324,"primaryCompletion":791,"completion":792,"start":793,"enrollment":794,"conditions":1325,"interventions":1326},[90],[796],[798,746],{"trials":1328,"activeCount":99},[],{"intervention":1330,"totalTrials":128,"cells":1331},"Sildenafil",{"EARLY_PHASE1":1332,"PHASE1":1334,"PHASE2":1336,"PHASE3":1338,"PHASE4":1340,"NA":1352},{"trials":1333,"activeCount":99},[],{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[],{"trials":1341,"activeCount":99},[1342],{"nctId":1343,"briefTitle":1344,"status":105,"phases":1345,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":475,"conditions":1348,"interventions":1350},"NCT00964782","The Effects of Sildenafil on Exercise Function and Capacity in Patients With Fontan Circulation",[90],"2012-05-24","2009-08",[1349],"Fontan Circulation",[1330,1351],"Sildenafil 2",{"trials":1353,"activeCount":99},[],{"intervention":1351,"totalTrials":128,"cells":1355},{"EARLY_PHASE1":1356,"PHASE1":1358,"PHASE2":1360,"PHASE3":1362,"PHASE4":1364,"NA":1370},{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":99},[],{"trials":1363,"activeCount":99},[],{"trials":1365,"activeCount":99},[1366],{"nctId":1343,"briefTitle":1344,"status":105,"phases":1367,"primaryCompletion":1346,"completion":1346,"start":1347,"enrollment":475,"conditions":1368,"interventions":1369},[90],[1349],[1330,1351],{"trials":1371,"activeCount":99},[],{"intervention":1373,"totalTrials":128,"cells":1374},"Oxytocin",{"EARLY_PHASE1":1375,"PHASE1":1377,"PHASE2":1379,"PHASE3":1381,"PHASE4":1383,"NA":1395},{"trials":1376,"activeCount":99},[],{"trials":1378,"activeCount":99},[],{"trials":1380,"activeCount":99},[],{"trials":1382,"activeCount":99},[],{"trials":1384,"activeCount":99},[1385],{"nctId":1386,"briefTitle":1387,"status":1120,"phases":1388,"primaryCompletion":1389,"completion":1389,"start":1390,"enrollment":99,"conditions":1391,"interventions":1394},"NCT03361124","Oxytocin Dosing at Planned Cesarean Section and Anemia",[90],"2020-03-01","2019-03-01",[1392,1393],"Blood Loss Anemia","Uterine Atony With Hemorrhage",[1373],{"trials":1396,"activeCount":99},[],{"intervention":1398,"totalTrials":128,"cells":1399},"Immediate Release Methylphenidate",{"EARLY_PHASE1":1400,"PHASE1":1402,"PHASE2":1404,"PHASE3":1406,"PHASE4":1408,"NA":1419},{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[1410],{"nctId":1411,"briefTitle":1412,"status":147,"phases":1413,"primaryCompletion":1414,"completion":1414,"start":1028,"enrollment":1058,"conditions":1415,"interventions":1418},"NCT02638168","Effects of Evening Dose of Immediate Release Methylphenidate on Sleep in Children With ADHD",[90],"2018-06",[1416,1417],"Attention Deficit Disorder With Hyperactivity","Behavioral Insomnia of Childhood",[1398],{"trials":1420,"activeCount":99},[],{"intervention":1422,"totalTrials":128,"cells":1423},"Ketorolac",{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1430,"PHASE4":1432,"NA":1448},{"trials":1425,"activeCount":99},[],{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[1434],{"nctId":1435,"briefTitle":1436,"status":1120,"phases":1437,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":99,"conditions":1441,"interventions":1446},"NCT03319784","Analysis for NSAID VS Corticosteroid Shoulder Injection in Diabetic Patients",[90],"2020-09-05","2020-10-05","2018-09-05",[1442,1443,1444,1445],"Rotator Cuff Tear","Rotator Cuff Injury","Rotator Cuff Tendinitis","Diabetes Mellitus",[1422,1447],"Triamcinolone Acetonide",{"trials":1449,"activeCount":99},[],{"intervention":1447,"totalTrials":128,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1458,"PHASE4":1460,"NA":1466},{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":99},[],{"trials":1459,"activeCount":99},[],{"trials":1461,"activeCount":99},[1462],{"nctId":1435,"briefTitle":1436,"status":1120,"phases":1463,"primaryCompletion":1438,"completion":1439,"start":1440,"enrollment":99,"conditions":1464,"interventions":1465},[90],[1442,1443,1444,1445],[1422,1447],{"trials":1467,"activeCount":99},[],{"intervention":1469,"totalTrials":128,"cells":1470},"Advair 250",{"EARLY_PHASE1":1471,"PHASE1":1473,"PHASE2":1475,"PHASE3":1477,"PHASE4":1479,"NA":1490},{"trials":1472,"activeCount":99},[],{"trials":1474,"activeCount":99},[],{"trials":1476,"activeCount":99},[],{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[1481],{"nctId":1482,"briefTitle":1483,"status":105,"phases":1484,"primaryCompletion":525,"completion":525,"start":1485,"enrollment":528,"conditions":1486,"interventions":1488},"NCT00731770","Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep",[90],"2009-01",[1487],"COPD",[1469,1489],"Advair 250 - matched",{"trials":1491,"activeCount":99},[],{"intervention":1489,"totalTrials":128,"cells":1493},{"EARLY_PHASE1":1494,"PHASE1":1496,"PHASE2":1498,"PHASE3":1500,"PHASE4":1502,"NA":1508},{"trials":1495,"activeCount":99},[],{"trials":1497,"activeCount":99},[],{"trials":1499,"activeCount":99},[],{"trials":1501,"activeCount":99},[],{"trials":1503,"activeCount":99},[1504],{"nctId":1482,"briefTitle":1483,"status":105,"phases":1505,"primaryCompletion":525,"completion":525,"start":1485,"enrollment":528,"conditions":1506,"interventions":1507},[90],[1487],[1469,1489],{"trials":1509,"activeCount":99},[],{"intervention":1511,"totalTrials":128,"cells":1512},"IV acetaminophen",{"EARLY_PHASE1":1513,"PHASE1":1515,"PHASE2":1517,"PHASE3":1519,"PHASE4":1521,"NA":1536},{"trials":1514,"activeCount":99},[],{"trials":1516,"activeCount":99},[],{"trials":1518,"activeCount":99},[],{"trials":1520,"activeCount":99},[],{"trials":1522,"activeCount":99},[1523],{"nctId":1524,"briefTitle":1525,"status":147,"phases":1526,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1058,"conditions":1529,"interventions":1532},"NCT02549716","Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH",[90],"2018-06-08","2017-01-05",[1530,1531],"Subarachnoid Hemorrhage","Stroke",[1511,1533,1534,1535],"Oral acetaminophen","Oral placebo","IV placebo",{"trials":1537,"activeCount":99},[],{"intervention":1533,"totalTrials":128,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1548,"NA":1554},{"trials":1541,"activeCount":99},[],{"trials":1543,"activeCount":99},[],{"trials":1545,"activeCount":99},[],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[1550],{"nctId":1524,"briefTitle":1525,"status":147,"phases":1551,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1058,"conditions":1552,"interventions":1553},[90],[1530,1531],[1511,1533,1534,1535],{"trials":1555,"activeCount":99},[],{"intervention":1534,"totalTrials":128,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1566,"NA":1572},{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":99},[],{"trials":1563,"activeCount":99},[],{"trials":1565,"activeCount":99},[],{"trials":1567,"activeCount":99},[1568],{"nctId":1524,"briefTitle":1525,"status":147,"phases":1569,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1058,"conditions":1570,"interventions":1571},[90],[1530,1531],[1511,1533,1534,1535],{"trials":1573,"activeCount":99},[],{"intervention":1535,"totalTrials":128,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1584,"NA":1590},{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[1586],{"nctId":1524,"briefTitle":1525,"status":147,"phases":1587,"primaryCompletion":1527,"completion":1527,"start":1528,"enrollment":1058,"conditions":1588,"interventions":1589},[90],[1530,1531],[1511,1533,1534,1535],{"trials":1591,"activeCount":99},[],{"intervention":1593,"totalTrials":128,"cells":1594},"Modafinil",{"EARLY_PHASE1":1595,"PHASE1":1597,"PHASE2":1599,"PHASE3":1601,"PHASE4":1603,"NA":1616},{"trials":1596,"activeCount":99},[],{"trials":1598,"activeCount":99},[],{"trials":1600,"activeCount":99},[],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[1605],{"nctId":1606,"briefTitle":1607,"status":147,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1615},"NCT02494102","Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea",[90],"2018-04-01","2016-02",105,[1613,1614],"Obstructive Sleep Apnea","Delayed Emergence From Anesthesia",[1593],{"trials":1617,"activeCount":99},[],{"intervention":1179,"totalTrials":128,"cells":1619},{"EARLY_PHASE1":1620,"PHASE1":1622,"PHASE2":1624,"PHASE3":1626,"PHASE4":1628,"NA":1634},{"trials":1621,"activeCount":99},[],{"trials":1623,"activeCount":99},[],{"trials":1625,"activeCount":99},[],{"trials":1627,"activeCount":99},[],{"trials":1629,"activeCount":99},[1630],{"nctId":1170,"briefTitle":1171,"status":147,"phases":1631,"primaryCompletion":1173,"completion":1173,"start":1174,"enrollment":1175,"conditions":1632,"interventions":1633},[90],[1177],[1179,1146],{"trials":1635,"activeCount":99},[],{"intervention":1637,"totalTrials":128,"cells":1638},"Gabapentin",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1647,"NA":1658},{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[1649],{"nctId":1650,"briefTitle":1651,"status":105,"phases":1652,"primaryCompletion":1070,"completion":1070,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1657},"NCT02359110","Administration of Pre-Operative Gabapentin to Patients Undergoing Laparoscopy",[90],"2015-06",112,[1656],"Postoperative Pain",[1637],{"trials":1659,"activeCount":99},[],{"intervention":1661,"totalTrials":128,"cells":1662},"Norethindrone Acetate 5 MG",{"EARLY_PHASE1":1663,"PHASE1":1665,"PHASE2":1667,"PHASE3":1669,"PHASE4":1671,"NA":1683},{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[],{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[1673],{"nctId":1674,"briefTitle":1675,"status":105,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":774,"conditions":1679,"interventions":1681},"NCT05294341","Metabolism of 0.35mg Norethindrone vs 5mg Norethindrone Acetate",[90],"2023-05-01","2022-07-22",[1680],"Contraception",[1661,1682],"Norethindrone 0.35 MG",{"trials":1684,"activeCount":99},[],{"intervention":1682,"totalTrials":128,"cells":1686},{"EARLY_PHASE1":1687,"PHASE1":1689,"PHASE2":1691,"PHASE3":1693,"PHASE4":1695,"NA":1701},{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[1697],{"nctId":1674,"briefTitle":1675,"status":105,"phases":1698,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":774,"conditions":1699,"interventions":1700},[90],[1680],[1661,1682],{"trials":1702,"activeCount":99},[],{"intervention":1704,"totalTrials":128,"cells":1705},"ethyl chloride",{"EARLY_PHASE1":1706,"PHASE1":1708,"PHASE2":1710,"PHASE3":1712,"PHASE4":1714,"NA":1727},{"trials":1707,"activeCount":99},[],{"trials":1709,"activeCount":99},[],{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":99},[],{"trials":1715,"activeCount":99},[1716],{"nctId":1717,"briefTitle":1718,"status":147,"phases":1719,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":1235,"conditions":1722,"interventions":1724},"NCT02592629","The Efficacy of Local Anesthetics to Reduce Shoulder Pain Post-Steroid Injections",[90],"2017-06-20","2016-02-01",[1723],"Shoulder Pain",[1725,1704,1726],"lidocaine","Kenalog",{"trials":1728,"activeCount":99},[],{"intervention":1726,"totalTrials":128,"cells":1730},{"EARLY_PHASE1":1731,"PHASE1":1733,"PHASE2":1735,"PHASE3":1737,"PHASE4":1739,"NA":1745},{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[1741],{"nctId":1717,"briefTitle":1718,"status":147,"phases":1742,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":1235,"conditions":1743,"interventions":1744},[90],[1723],[1725,1704,1726],{"trials":1746,"activeCount":99},[],{"intervention":1748,"totalTrials":128,"cells":1749},"transdermal Megace",{"EARLY_PHASE1":1750,"PHASE1":1752,"PHASE2":1754,"PHASE3":1756,"PHASE4":1758,"NA":1768},{"trials":1751,"activeCount":99},[],{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[1760],{"nctId":1761,"briefTitle":1762,"status":1120,"phases":1763,"primaryCompletion":107,"completion":107,"start":1764,"enrollment":99,"conditions":1765,"interventions":1767},"NCT00163072","Pharmacokinetics and Safety of Transdermal Megestrol Acetate",[90],"2005-10",[1766],"Cachexia",[1748],{"trials":1769,"activeCount":99},[],{"intervention":1771,"totalTrials":128,"cells":1772},"atenolol",{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1779,"PHASE4":1781,"NA":1794},{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":99},[],{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[1783],{"nctId":1784,"briefTitle":1785,"status":105,"phases":1786,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1789,"conditions":1790,"interventions":1792},"NCT02441842","Evaluation of Periop Biochemical Stress Factors in Craniotomy Neurosurgical Procedure With Respect to Preop Hypertension",[90],"2008-12","2006-03",85,[1791],"Perioperative Hypertension",[1771,1793],"lisinopril",{"trials":1795,"activeCount":99},[],{"intervention":1793,"totalTrials":128,"cells":1797},{"EARLY_PHASE1":1798,"PHASE1":1800,"PHASE2":1802,"PHASE3":1804,"PHASE4":1806,"NA":1812},{"trials":1799,"activeCount":99},[],{"trials":1801,"activeCount":99},[],{"trials":1803,"activeCount":99},[],{"trials":1805,"activeCount":99},[],{"trials":1807,"activeCount":99},[1808],{"nctId":1784,"briefTitle":1785,"status":105,"phases":1809,"primaryCompletion":1787,"completion":1787,"start":1788,"enrollment":1789,"conditions":1810,"interventions":1811},[90],[1791],[1771,1793],{"trials":1813,"activeCount":99},[],{"intervention":1815,"totalTrials":128,"cells":1816},"ionic iron",{"EARLY_PHASE1":1817,"PHASE1":1819,"PHASE2":1821,"PHASE3":1823,"PHASE4":1825,"NA":1836},{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":99},[],{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[1827],{"nctId":1828,"briefTitle":1829,"status":1120,"phases":1830,"primaryCompletion":1831,"completion":1831,"start":1028,"enrollment":99,"conditions":1832,"interventions":1834},"NCT01865175","A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron",[90],"2016-05",[1833],"Iron Deficiency",[1815,1835],"heme iron polypeptide",{"trials":1837,"activeCount":99},[],{"intervention":1835,"totalTrials":128,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1846,"PHASE4":1848,"NA":1854},{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[],{"trials":1845,"activeCount":99},[],{"trials":1847,"activeCount":99},[],{"trials":1849,"activeCount":99},[1850],{"nctId":1828,"briefTitle":1829,"status":1120,"phases":1851,"primaryCompletion":1831,"completion":1831,"start":1028,"enrollment":99,"conditions":1852,"interventions":1853},[90],[1833],[1815,1835],{"trials":1855,"activeCount":99},[],{"intervention":1857,"totalTrials":128,"cells":1858},"phenylephrine",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1865,"PHASE4":1867,"NA":1880},{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":99},[],{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[1869],{"nctId":1870,"briefTitle":1871,"status":105,"phases":1872,"primaryCompletion":1873,"completion":1874,"start":1875,"enrollment":1876,"conditions":1877,"interventions":1879},"NCT00846651","Spinal Anesthesia Induced Hypotension During Cesarean Section",[90],"2009-12","2010-02","2009-02",82,[1878],"Hypotension",[1857],{"trials":1881,"activeCount":99},[],{"intervention":1883,"totalTrials":128,"cells":1884},"Cimzia",{"EARLY_PHASE1":1885,"PHASE1":1887,"PHASE2":1889,"PHASE3":1891,"PHASE4":1893,"NA":1905},{"trials":1886,"activeCount":99},[],{"trials":1888,"activeCount":99},[],{"trials":1890,"activeCount":99},[],{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[1895],{"nctId":1896,"briefTitle":1897,"status":147,"phases":1898,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":528,"conditions":1901,"interventions":1903},"NCT01696942","Cimzia Versus Mesalamine for Crohn's Recurrence",[90],"2016-06","2013-02",[1902],"Crohn's Disease",[1883,1904],"Mesalamine",{"trials":1906,"activeCount":99},[],{"intervention":1904,"totalTrials":128,"cells":1908},{"EARLY_PHASE1":1909,"PHASE1":1911,"PHASE2":1913,"PHASE3":1915,"PHASE4":1917,"NA":1923},{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[],{"trials":1916,"activeCount":99},[],{"trials":1918,"activeCount":99},[1919],{"nctId":1896,"briefTitle":1897,"status":147,"phases":1920,"primaryCompletion":1899,"completion":1899,"start":1900,"enrollment":528,"conditions":1921,"interventions":1922},[90],[1902],[1883,1904],{"trials":1924,"activeCount":99},[],{"intervention":1076,"totalTrials":95,"cells":1926},{"EARLY_PHASE1":1927,"PHASE1":1929,"PHASE2":1931,"PHASE3":1937,"PHASE4":1943,"NA":1945},{"trials":1928,"activeCount":99},[],{"trials":1930,"activeCount":99},[],{"trials":1932,"activeCount":99},[1933],{"nctId":1067,"briefTitle":1068,"status":105,"phases":1934,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":1935,"interventions":1936},[88],[1074],[1076,1077,1078],{"trials":1938,"activeCount":99},[1939],{"nctId":1082,"briefTitle":1083,"status":147,"phases":1940,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":1941,"interventions":1942},[89],[1090,1091],[1076,1057,1093],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"intervention":1948,"totalTrials":95,"cells":1949},"Norethindrone Acetate",{"EARLY_PHASE1":1950,"PHASE1":1952,"PHASE2":1954,"PHASE3":1956,"PHASE4":1979,"NA":1981},{"trials":1951,"activeCount":99},[],{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[1958,1970],{"nctId":1959,"briefTitle":1960,"status":147,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":733,"conditions":1965,"interventions":1968},"NCT04527003","Cannabidiol and Management of Endometriosis Pain",[89],"2024-05-29","2024-06-26","2020-12-04",[28,1966,1967],"CBD","Pelvic Pain",[1969,1948],"Cannabidiol (CBD) Extract",{"nctId":1971,"briefTitle":1972,"status":147,"phases":1973,"primaryCompletion":1974,"completion":1974,"start":1975,"enrollment":21,"conditions":1976,"interventions":1977},"NCT03970330","Low-Dose Naltrexone in Combination With Standard Treatment in Women With Endometriosis",[89],"2021-06-21","2020-01-16",[28],[1978,1948],"Naltrexone",{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[],{"intervention":1984,"totalTrials":95,"cells":1985},"Acetaminophen",{"EARLY_PHASE1":1986,"PHASE1":1988,"PHASE2":1990,"PHASE3":1992,"PHASE4":2015,"NA":2017},{"trials":1987,"activeCount":99},[],{"trials":1989,"activeCount":99},[],{"trials":1991,"activeCount":99},[],{"trials":1993,"activeCount":99},[1994,2004],{"nctId":1995,"briefTitle":1996,"status":105,"phases":1997,"primaryCompletion":1998,"completion":1998,"start":1900,"enrollment":1999,"conditions":2000,"interventions":2002},"NCT01606319","Acetaminophen Versus Ibuprofen in Children With Asthma",[89],"2015-04",300,[14,2001],"Wheezing",[1984,2003],"Ibuprofen",{"nctId":2005,"briefTitle":2006,"status":147,"phases":2007,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2012,"interventions":2014},"NCT03929640","Management Of Pain After Cesarean Trial",[89],"2020-03-14","2020-03-26","2019-08-05",49,[112,2013],"Opioid Use",[1984,2003],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"intervention":2003,"totalTrials":95,"cells":2020},{"EARLY_PHASE1":2021,"PHASE1":2023,"PHASE2":2025,"PHASE3":2027,"PHASE4":2037,"NA":2039},{"trials":2022,"activeCount":99},[],{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[2029,2033],{"nctId":1995,"briefTitle":1996,"status":105,"phases":2030,"primaryCompletion":1998,"completion":1998,"start":1900,"enrollment":1999,"conditions":2031,"interventions":2032},[89],[14,2001],[1984,2003],{"nctId":2005,"briefTitle":2006,"status":147,"phases":2034,"primaryCompletion":2008,"completion":2009,"start":2010,"enrollment":2011,"conditions":2035,"interventions":2036},[89],[112,2013],[1984,2003],{"trials":2038,"activeCount":99},[],{"trials":2040,"activeCount":99},[],{"intervention":2042,"totalTrials":95,"cells":2043},"fluticasone propionate",{"EARLY_PHASE1":2044,"PHASE1":2046,"PHASE2":2048,"PHASE3":2050,"PHASE4":2073,"NA":2075},{"trials":2045,"activeCount":99},[],{"trials":2047,"activeCount":99},[],{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[2052,2063],{"nctId":2053,"briefTitle":2054,"status":105,"phases":2055,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":2058,"conditions":2059,"interventions":2060},"NCT00395304","Childhood Asthma Research and Education (CARE) Network Trial - Best Add-On Therapy Giving Effective Response (BADGER)",[89],"2011-12","2007-03",182,[14],[2061,2042,2062],"fluticasone propionate + montelukast","fluticasone propionate + salmeterol",{"nctId":2064,"briefTitle":2065,"status":105,"phases":2066,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2070,"interventions":2071},"NCT00318708","Asthma Clinical Research Network (ACRN) Trial - Macrolides in Asthma (MIA)",[89],"2009-04","2006-06",92,[14],[2072,2042],"clarithromycin",{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"intervention":2078,"totalTrials":95,"cells":2079},"Beclomethasone dipropionate",{"EARLY_PHASE1":2080,"PHASE1":2082,"PHASE2":2084,"PHASE3":2086,"PHASE4":2108,"NA":2110},{"trials":2081,"activeCount":99},[],{"trials":2083,"activeCount":99},[],{"trials":2085,"activeCount":99},[],{"trials":2087,"activeCount":99},[2088,2097],{"nctId":2089,"briefTitle":2090,"status":105,"phases":2091,"primaryCompletion":2056,"completion":2056,"start":2092,"enrollment":2093,"conditions":2094,"interventions":2095},"NCT00394329","(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)",[89],"2006-11",288,[14],[2078,2078,2096],"Albuterol sulfate",{"nctId":2098,"briefTitle":2099,"status":105,"phases":2100,"primaryCompletion":474,"completion":474,"start":2101,"enrollment":2102,"conditions":2103,"interventions":2104},"NCT00565266","Asthma Clinical Research Network (ACRN) Trial - Tiotropium Bromide as an Alternative to Increased Inhaled Corticosteroid in Patients Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC)",[89],"2008-05",210,[14],[2105,2106,2107],"tiotropium bromide","salmeterol xinafoate","beclomethasone dipropionate",{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"intervention":2113,"totalTrials":95,"cells":2114},"Colchicine",{"EARLY_PHASE1":2115,"PHASE1":2117,"PHASE2":2119,"PHASE3":2129,"PHASE4":2143,"NA":2145},{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[],{"trials":2120,"activeCount":99},[2121],{"nctId":2122,"briefTitle":2123,"status":1120,"phases":2124,"primaryCompletion":2125,"completion":2125,"start":2126,"enrollment":99,"conditions":2127,"interventions":2128},"NCT01481233","Oral Colchicine in Men With Castrate Resistant Prostate Cancer",[88],"2013-08","2013-05",[639],[2113],{"trials":2130,"activeCount":99},[2131],{"nctId":2132,"briefTitle":2133,"status":1120,"phases":2134,"completion":2135,"start":2136,"enrollment":99,"conditions":2137,"interventions":2139},"NCT00000577","Asthma Clinical Research Network (ACRN)",[89],"2008-07","1993-09",[14,2138],"Lung Diseases",[2140,2113,2141,2142],"Albuterol","Adrenal Cortex Hormones","Adrenergic-Beta Agonists",{"trials":2144,"activeCount":99},[],{"trials":2146,"activeCount":99},[],{"intervention":1978,"totalTrials":95,"cells":2148},{"EARLY_PHASE1":2149,"PHASE1":2151,"PHASE2":2153,"PHASE3":2163,"PHASE4":2169,"NA":2171},{"trials":2150,"activeCount":99},[],{"trials":2152,"activeCount":99},[],{"trials":2154,"activeCount":99},[2155],{"nctId":2156,"briefTitle":2157,"status":105,"phases":2158,"primaryCompletion":474,"completion":2159,"start":2135,"enrollment":2160,"conditions":2161,"interventions":2162},"NCT00715117","The Efficacy of Low Dose Naltrexone Therapy in Children With Crohn's Disease",[88],"2010-08",14,[1902],[1978],{"trials":2164,"activeCount":99},[2165],{"nctId":1971,"briefTitle":1972,"status":147,"phases":2166,"primaryCompletion":1974,"completion":1974,"start":1975,"enrollment":21,"conditions":2167,"interventions":2168},[89],[28],[1978,1948],{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"intervention":2174,"totalTrials":128,"cells":2175},"Azithromycin",{"EARLY_PHASE1":2176,"PHASE1":2178,"PHASE2":2180,"PHASE3":2182,"PHASE4":2193,"NA":2195},{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":2185,"briefTitle":2186,"status":105,"phases":2187,"primaryCompletion":2188,"completion":2188,"start":496,"enrollment":2189,"conditions":2190,"interventions":2191},"NCT01272635","Treatment of Preschool Children With Upper Respiratory Tract Illnesses Using Azythromycin and Lower Respiratory Tract Symptoms Using Oral Corticosteroids.",[89],"2015-01",607,[14,2001],[2174,2192],"Prednisolone",{"trials":2194,"activeCount":99},[],{"trials":2196,"activeCount":99},[],{"intervention":2192,"totalTrials":128,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2203,"PHASE3":2205,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":99},[],{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[2207],{"nctId":2185,"briefTitle":2186,"status":105,"phases":2208,"primaryCompletion":2188,"completion":2188,"start":496,"enrollment":2189,"conditions":2209,"interventions":2210},[89],[14,2001],[2174,2192],{"trials":2212,"activeCount":99},[],{"trials":2214,"activeCount":99},[],{"intervention":2216,"totalTrials":128,"cells":2217},"Fluticasone 44 mcg",{"EARLY_PHASE1":2218,"PHASE1":2220,"PHASE2":2222,"PHASE3":2224,"PHASE4":2236,"NA":2238},{"trials":2219,"activeCount":99},[],{"trials":2221,"activeCount":99},[],{"trials":2223,"activeCount":99},[],{"trials":2225,"activeCount":99},[2226],{"nctId":2227,"briefTitle":2228,"status":105,"phases":2229,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2233,"interventions":2234},"NCT02066129","Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations",[89],"2017-04-21","2014-07",254,[14],[2216,2235],"Fluticasone 220 mcg",{"trials":2237,"activeCount":99},[],{"trials":2239,"activeCount":99},[],{"intervention":2235,"totalTrials":128,"cells":2241},{"EARLY_PHASE1":2242,"PHASE1":2244,"PHASE2":2246,"PHASE3":2248,"PHASE4":2254,"NA":2256},{"trials":2243,"activeCount":99},[],{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[2250],{"nctId":2227,"briefTitle":2228,"status":105,"phases":2251,"primaryCompletion":2230,"completion":2230,"start":2231,"enrollment":2232,"conditions":2252,"interventions":2253},[89],[14],[2216,2235],{"trials":2255,"activeCount":99},[],{"trials":2257,"activeCount":99},[],{"intervention":2259,"totalTrials":128,"cells":2260},"Calfactant",{"EARLY_PHASE1":2261,"PHASE1":2263,"PHASE2":2265,"PHASE3":2267,"PHASE4":2280,"NA":2282},{"trials":2262,"activeCount":99},[],{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[],{"trials":2268,"activeCount":99},[2269],{"nctId":2270,"briefTitle":2271,"status":105,"phases":2272,"primaryCompletion":2273,"completion":2274,"start":2275,"enrollment":2276,"conditions":2277,"interventions":2279},"NCT00999713","CALIPSO: Calfactant for Acute Lung Injury in Pediatric Stem Cell Transplant and Oncology Patients",[88,89],"2015-09","2015-10","2010-06",43,[2278],"Acute Lung Injury",[2259],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"intervention":1969,"totalTrials":128,"cells":2285},{"EARLY_PHASE1":2286,"PHASE1":2288,"PHASE2":2290,"PHASE3":2292,"PHASE4":2298,"NA":2300},{"trials":2287,"activeCount":99},[],{"trials":2289,"activeCount":99},[],{"trials":2291,"activeCount":99},[],{"trials":2293,"activeCount":99},[2294],{"nctId":1959,"briefTitle":1960,"status":147,"phases":2295,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":733,"conditions":2296,"interventions":2297},[89],[28,1966,1967],[1969,1948],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"intervention":2303,"totalTrials":128,"cells":2304},"Vitamin D3",{"EARLY_PHASE1":2305,"PHASE1":2307,"PHASE2":2309,"PHASE3":2311,"PHASE4":2322,"NA":2324},{"trials":2306,"activeCount":99},[],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[2313],{"nctId":2314,"briefTitle":2315,"status":105,"phases":2316,"primaryCompletion":2317,"completion":2317,"start":1008,"enrollment":2318,"conditions":2319,"interventions":2320},"NCT01248065","Study of the Effect of Vitamin D as an Add-on Therapy to Corticosteroids in Asthma",[89],"2014-01",408,[14],[2303,2321],"Ciclesonide",{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"intervention":2321,"totalTrials":128,"cells":2327},{"EARLY_PHASE1":2328,"PHASE1":2330,"PHASE2":2332,"PHASE3":2334,"PHASE4":2340,"NA":2342},{"trials":2329,"activeCount":99},[],{"trials":2331,"activeCount":99},[],{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[2336],{"nctId":2314,"briefTitle":2315,"status":105,"phases":2337,"primaryCompletion":2317,"completion":2317,"start":1008,"enrollment":2318,"conditions":2338,"interventions":2339},[89],[14],[2303,2321],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[],{"intervention":2345,"totalTrials":128,"cells":2346},"Pulmozyme single use ampule",{"EARLY_PHASE1":2347,"PHASE1":2349,"PHASE2":2351,"PHASE3":2353,"PHASE4":2365,"NA":2367},{"trials":2348,"activeCount":99},[],{"trials":2350,"activeCount":99},[],{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[2355],{"nctId":2356,"briefTitle":2357,"status":1120,"phases":2358,"primaryCompletion":2359,"completion":1653,"start":2360,"enrollment":99,"conditions":2361,"interventions":2364},"NCT01155752","Pulmozyme in Cystic Fibrosis With Sinusitis",[89],"2014-06","2013-07",[2362,2363],"Sinusitis","Cystic Fibrosis",[2345],{"trials":2366,"activeCount":99},[],{"trials":2368,"activeCount":99},[],{"intervention":2370,"totalTrials":128,"cells":2371},"Topical lidocaine",{"EARLY_PHASE1":2372,"PHASE1":2374,"PHASE2":2376,"PHASE3":2378,"PHASE4":2398,"NA":2400},{"trials":2373,"activeCount":99},[],{"trials":2375,"activeCount":99},[],{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[2380],{"nctId":2381,"briefTitle":2382,"status":147,"phases":2383,"primaryCompletion":2384,"completion":2384,"start":2385,"enrollment":2386,"conditions":2387,"interventions":2395},"NCT03829618","Lidocaine Administration During Flexible Bronchoscopy and Endobronchial Ultrasound",[89],"2020-08-31","2019-04-01",29,[2388,2389,2390,2391,2392,2393,2394],"Bronchiectasis Adult","Mediastinal Lymphadenopathy","Pneumonia","Chest--Diseases","Infiltrates","Bronchopulmonary Disease","Cancer, Lung",[2370,2396,2397],"Nebuliser solution","Nebuliser Suspension",{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[],{"intervention":2396,"totalTrials":128,"cells":2403},{"EARLY_PHASE1":2404,"PHASE1":2406,"PHASE2":2408,"PHASE3":2410,"PHASE4":2416,"NA":2418},{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[],{"trials":2411,"activeCount":99},[2412],{"nctId":2381,"briefTitle":2382,"status":147,"phases":2413,"primaryCompletion":2384,"completion":2384,"start":2385,"enrollment":2386,"conditions":2414,"interventions":2415},[89],[2388,2389,2390,2391,2392,2393,2394],[2370,2396,2397],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"intervention":2397,"totalTrials":128,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2428,"PHASE4":2434,"NA":2436},{"trials":2423,"activeCount":99},[],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[2430],{"nctId":2381,"briefTitle":2382,"status":147,"phases":2431,"primaryCompletion":2384,"completion":2384,"start":2385,"enrollment":2386,"conditions":2432,"interventions":2433},[89],[2388,2389,2390,2391,2392,2393,2394],[2370,2396,2397],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"intervention":2439,"totalTrials":128,"cells":2440},"Zometa",{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2447,"PHASE4":2456,"NA":2458},{"trials":2442,"activeCount":99},[],{"trials":2444,"activeCount":99},[],{"trials":2446,"activeCount":99},[],{"trials":2448,"activeCount":99},[2449],{"nctId":2450,"briefTitle":2451,"status":105,"phases":2452,"primaryCompletion":496,"completion":496,"start":2453,"enrollment":941,"conditions":2454,"interventions":2455},"NCT00712985","Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)",[89],"2005-09",[17],[2439],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"intervention":2461,"totalTrials":128,"cells":2462},"daily fluticasone propionate",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2467,"PHASE3":2469,"PHASE4":2479,"NA":2481},{"trials":2464,"activeCount":99},[],{"trials":2466,"activeCount":99},[],{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[2471],{"nctId":2472,"briefTitle":2473,"status":105,"phases":2474,"primaryCompletion":1998,"completion":1998,"start":1900,"enrollment":1999,"conditions":2475,"interventions":2476},"NCT01606306","Individualized Therapy For Asthma in Toddlers",[89],[14,2001],[2461,2477,2478],"Montelukast","as-needed fluticasone propionate",{"trials":2480,"activeCount":99},[],{"trials":2482,"activeCount":99},[],{"intervention":2477,"totalTrials":128,"cells":2484},{"EARLY_PHASE1":2485,"PHASE1":2487,"PHASE2":2489,"PHASE3":2491,"PHASE4":2497,"NA":2499},{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[],{"trials":2490,"activeCount":99},[],{"trials":2492,"activeCount":99},[2493],{"nctId":2472,"briefTitle":2473,"status":105,"phases":2494,"primaryCompletion":1998,"completion":1998,"start":1900,"enrollment":1999,"conditions":2495,"interventions":2496},[89],[14,2001],[2461,2477,2478],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"intervention":2478,"totalTrials":128,"cells":2502},{"EARLY_PHASE1":2503,"PHASE1":2505,"PHASE2":2507,"PHASE3":2509,"PHASE4":2515,"NA":2517},{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"trials":2508,"activeCount":99},[],{"trials":2510,"activeCount":99},[2511],{"nctId":2472,"briefTitle":2473,"status":105,"phases":2512,"primaryCompletion":1998,"completion":1998,"start":1900,"enrollment":1999,"conditions":2513,"interventions":2514},[89],[14,2001],[2461,2477,2478],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"intervention":2520,"totalTrials":128,"cells":2521},"TAP block w Liposomal bupivacaine",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2537,"NA":2539},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[2530],{"nctId":2531,"briefTitle":2532,"status":1120,"phases":2533,"primaryCompletion":2534,"enrollment":99,"conditions":2535,"interventions":2536},"NCT02847013","The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section",[88,89],"2019-12-17",[23],[2520],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"intervention":2542,"totalTrials":128,"cells":2543},"4-Aminopyridine",{"EARLY_PHASE1":2544,"PHASE1":2546,"PHASE2":2548,"PHASE3":2550,"PHASE4":2561,"NA":2563},{"trials":2545,"activeCount":99},[],{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[2552],{"nctId":2553,"briefTitle":2554,"status":147,"phases":2555,"primaryCompletion":2556,"completion":2556,"start":2557,"enrollment":128,"conditions":2558,"interventions":2560},"NCT04026568","A Single Dose Pharmaco-Diagnostic for Peripheral Nerve Continuity After Trauma",[88,89],"2022-07-18","2021-08-17",[2559],"Nerve Injury",[2542],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"intervention":2061,"totalTrials":128,"cells":2566},{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2579,"NA":2581},{"trials":2568,"activeCount":99},[],{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[],{"trials":2574,"activeCount":99},[2575],{"nctId":2053,"briefTitle":2054,"status":105,"phases":2576,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":2058,"conditions":2577,"interventions":2578},[89],[14],[2061,2042,2062],{"trials":2580,"activeCount":99},[],{"trials":2582,"activeCount":99},[],{"intervention":2062,"totalTrials":128,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2597,"NA":2599},{"trials":2586,"activeCount":99},[],{"trials":2588,"activeCount":99},[],{"trials":2590,"activeCount":99},[],{"trials":2592,"activeCount":99},[2593],{"nctId":2053,"briefTitle":2054,"status":105,"phases":2594,"primaryCompletion":2056,"completion":2056,"start":2057,"enrollment":2058,"conditions":2595,"interventions":2596},[89],[14],[2061,2042,2062],{"trials":2598,"activeCount":99},[],{"trials":2600,"activeCount":99},[],{"intervention":2602,"totalTrials":128,"cells":2603},"Budesonide",{"EARLY_PHASE1":2604,"PHASE1":2606,"PHASE2":2608,"PHASE3":2610,"PHASE4":2621,"NA":2623},{"trials":2605,"activeCount":99},[],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"trials":2611,"activeCount":99},[2612],{"nctId":2613,"briefTitle":2614,"status":105,"phases":2615,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2620},"NCT00675584","CARE Network Maintenance Versus Intermittent Inhaled Steroids in Wheezing Toddlers (MIST)",[89],"2010-07","2008-08",278,[14],[2602],{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":99},[],{"intervention":2626,"totalTrials":128,"cells":2627},"Pseudoephedrine",{"EARLY_PHASE1":2628,"PHASE1":2630,"PHASE2":2632,"PHASE3":2634,"PHASE4":2645,"NA":2647},{"trials":2629,"activeCount":99},[],{"trials":2631,"activeCount":99},[],{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[2636],{"nctId":2637,"briefTitle":2638,"status":105,"phases":2639,"primaryCompletion":305,"completion":305,"start":2640,"enrollment":1260,"conditions":2641,"interventions":2644},"NCT00704496","The Effect of Pseudoephedrine on Rhinitis and Sleep",[89],"2007-06",[2642,2643],"Rhinitis","Sleep",[2626],{"trials":2646,"activeCount":99},[],{"trials":2648,"activeCount":99},[],{"intervention":2096,"totalTrials":128,"cells":2650},{"EARLY_PHASE1":2651,"PHASE1":2653,"PHASE2":2655,"PHASE3":2657,"PHASE4":2663,"NA":2665},{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[2659],{"nctId":2089,"briefTitle":2090,"status":105,"phases":2660,"primaryCompletion":2056,"completion":2056,"start":2092,"enrollment":2093,"conditions":2661,"interventions":2662},[89],[14],[2078,2078,2096],{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[],{"intervention":2105,"totalTrials":128,"cells":2668},{"EARLY_PHASE1":2669,"PHASE1":2671,"PHASE2":2673,"PHASE3":2675,"PHASE4":2681,"NA":2683},{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"trials":2674,"activeCount":99},[],{"trials":2676,"activeCount":99},[2677],{"nctId":2098,"briefTitle":2099,"status":105,"phases":2678,"primaryCompletion":474,"completion":474,"start":2101,"enrollment":2102,"conditions":2679,"interventions":2680},[89],[14],[2105,2106,2107],{"trials":2682,"activeCount":99},[],{"trials":2684,"activeCount":99},[],{"intervention":2106,"totalTrials":128,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[2695],{"nctId":2098,"briefTitle":2099,"status":105,"phases":2696,"primaryCompletion":474,"completion":474,"start":2101,"enrollment":2102,"conditions":2697,"interventions":2698},[89],[14],[2105,2106,2107],{"trials":2700,"activeCount":99},[],{"trials":2702,"activeCount":99},[],{"intervention":2704,"totalTrials":128,"cells":2705},"Oxymetazoline 0.1% (Pf) Oph Soln Ud",{"EARLY_PHASE1":2706,"PHASE1":2708,"PHASE2":2710,"PHASE3":2712,"PHASE4":2726,"NA":2728},{"trials":2707,"activeCount":99},[],{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[2714],{"nctId":2715,"briefTitle":2716,"status":105,"phases":2717,"primaryCompletion":2718,"completion":2718,"start":2719,"enrollment":9,"conditions":2720,"interventions":2725},"NCT05945615","Oxymetazoline Drops for Acquired Blepharoptosis From Synkinesis",[89],"2026-01-08","2024-01-11",[2721,2722,2723,2724],"Blepharoptosis","Synkinesis","Hyperkinesis","Facial Paralysis",[2704],{"trials":2727,"activeCount":99},[],{"trials":2729,"activeCount":99},[],{"intervention":2731,"totalTrials":128,"cells":2732},"salmeterol",{"EARLY_PHASE1":2733,"PHASE1":2735,"PHASE2":2737,"PHASE3":2739,"PHASE4":2751,"NA":2753},{"trials":2734,"activeCount":99},[],{"trials":2736,"activeCount":99},[],{"trials":2738,"activeCount":99},[],{"trials":2740,"activeCount":99},[2741],{"nctId":2742,"briefTitle":2743,"status":105,"phases":2744,"primaryCompletion":2745,"completion":2745,"start":2746,"enrollment":2747,"conditions":2748,"interventions":2749},"NCT00200967","Asthma Clinical Research Network (ACRN) Trial - Long-Acting Beta Agonist Response by Genotype (LARGE)",[89],"2008-02","2004-12",87,[14],[2731,2750],"beclomethasone HFA",{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[],{"intervention":2750,"totalTrials":128,"cells":2756},{"EARLY_PHASE1":2757,"PHASE1":2759,"PHASE2":2761,"PHASE3":2763,"PHASE4":2769,"NA":2771},{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[],{"trials":2762,"activeCount":99},[],{"trials":2764,"activeCount":99},[2765],{"nctId":2742,"briefTitle":2743,"status":105,"phases":2766,"primaryCompletion":2745,"completion":2745,"start":2746,"enrollment":2747,"conditions":2767,"interventions":2768},[89],[14],[2731,2750],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"intervention":2072,"totalTrials":128,"cells":2774},{"EARLY_PHASE1":2775,"PHASE1":2777,"PHASE2":2779,"PHASE3":2781,"PHASE4":2787,"NA":2789},{"trials":2776,"activeCount":99},[],{"trials":2778,"activeCount":99},[],{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":99},[2783],{"nctId":2064,"briefTitle":2065,"status":105,"phases":2784,"primaryCompletion":2067,"completion":2067,"start":2068,"enrollment":2069,"conditions":2785,"interventions":2786},[89],[14],[2072,2042],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[],{"intervention":2792,"totalTrials":128,"cells":2793},"Flovent Diskus® 100 mcg",{"EARLY_PHASE1":2794,"PHASE1":2796,"PHASE2":2798,"PHASE3":2800,"PHASE4":2815,"NA":2817},{"trials":2795,"activeCount":99},[],{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[2802],{"nctId":2803,"briefTitle":2804,"status":105,"phases":2805,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2809,"interventions":2810},"NCT01967173","Best African American Response to Asthma Drugs",[89],"2017-07-01","2014-02",574,[14],[2792,2811,2812,2813,2814],"Flovent Diskus® 250 mcg","Flovent Diskus® 500 mcg","Advair Diskus® 100\u002F50 mcg","Advair Diskus® 250\u002F50 mcg",{"trials":2816,"activeCount":99},[],{"trials":2818,"activeCount":99},[],{"intervention":2811,"totalTrials":128,"cells":2820},{"EARLY_PHASE1":2821,"PHASE1":2823,"PHASE2":2825,"PHASE3":2827,"PHASE4":2833,"NA":2835},{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[],{"trials":2828,"activeCount":99},[2829],{"nctId":2803,"briefTitle":2804,"status":105,"phases":2830,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2831,"interventions":2832},[89],[14],[2792,2811,2812,2813,2814],{"trials":2834,"activeCount":99},[],{"trials":2836,"activeCount":99},[],{"intervention":2812,"totalTrials":128,"cells":2838},{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2845,"PHASE4":2851,"NA":2853},{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[],{"trials":2846,"activeCount":99},[2847],{"nctId":2803,"briefTitle":2804,"status":105,"phases":2848,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2849,"interventions":2850},[89],[14],[2792,2811,2812,2813,2814],{"trials":2852,"activeCount":99},[],{"trials":2854,"activeCount":99},[],{"intervention":2813,"totalTrials":128,"cells":2856},{"EARLY_PHASE1":2857,"PHASE1":2859,"PHASE2":2861,"PHASE3":2863,"PHASE4":2869,"NA":2871},{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"trials":2864,"activeCount":99},[2865],{"nctId":2803,"briefTitle":2804,"status":105,"phases":2866,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2867,"interventions":2868},[89],[14],[2792,2811,2812,2813,2814],{"trials":2870,"activeCount":99},[],{"trials":2872,"activeCount":99},[],{"intervention":2814,"totalTrials":128,"cells":2874},{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2881,"PHASE4":2887,"NA":2889},{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[],{"trials":2882,"activeCount":99},[2883],{"nctId":2803,"briefTitle":2804,"status":105,"phases":2884,"primaryCompletion":2806,"completion":2806,"start":2807,"enrollment":2808,"conditions":2885,"interventions":2886},[89],[14],[2792,2811,2812,2813,2814],{"trials":2888,"activeCount":99},[],{"trials":2890,"activeCount":99},[],{"intervention":2892,"totalTrials":128,"cells":2893},"Suvorexant 20 mg",{"EARLY_PHASE1":2894,"PHASE1":2896,"PHASE2":2898,"PHASE3":2900,"PHASE4":2914,"NA":2916},{"trials":2895,"activeCount":99},[],{"trials":2897,"activeCount":99},[],{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[2902],{"nctId":2903,"briefTitle":2904,"status":105,"phases":2905,"primaryCompletion":2906,"completion":2906,"start":2907,"enrollment":2908,"conditions":2909,"interventions":2913},"NCT03412591","The Efficacy of Suvorexant in Treatment of Patients With Substance Use Disorder and Insomnia: A Pilot Open Trial",[88,89],"2023-01-07","2019-07-01",28,[2910,2911,2912],"Sleep Disturbance","Craving","Cortisol; Hypersecretion",[2892],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[],{"intervention":2140,"totalTrials":128,"cells":2919},{"EARLY_PHASE1":2920,"PHASE1":2922,"PHASE2":2924,"PHASE3":2926,"PHASE4":2932,"NA":2934},{"trials":2921,"activeCount":99},[],{"trials":2923,"activeCount":99},[],{"trials":2925,"activeCount":99},[],{"trials":2927,"activeCount":99},[2928],{"nctId":2132,"briefTitle":2133,"status":1120,"phases":2929,"completion":2135,"start":2136,"enrollment":99,"conditions":2930,"interventions":2931},[89],[14,2138],[2140,2113,2141,2142],{"trials":2933,"activeCount":99},[],{"trials":2935,"activeCount":99},[],{"intervention":2141,"totalTrials":128,"cells":2937},{"EARLY_PHASE1":2938,"PHASE1":2940,"PHASE2":2942,"PHASE3":2944,"PHASE4":2950,"NA":2952},{"trials":2939,"activeCount":99},[],{"trials":2941,"activeCount":99},[],{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[2946],{"nctId":2132,"briefTitle":2133,"status":1120,"phases":2947,"completion":2135,"start":2136,"enrollment":99,"conditions":2948,"interventions":2949},[89],[14,2138],[2140,2113,2141,2142],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"intervention":2142,"totalTrials":128,"cells":2955},{"EARLY_PHASE1":2956,"PHASE1":2958,"PHASE2":2960,"PHASE3":2962,"PHASE4":2968,"NA":2970},{"trials":2957,"activeCount":99},[],{"trials":2959,"activeCount":99},[],{"trials":2961,"activeCount":99},[],{"trials":2963,"activeCount":99},[2964],{"nctId":2132,"briefTitle":2133,"status":1120,"phases":2965,"completion":2135,"start":2136,"enrollment":99,"conditions":2966,"interventions":2967},[89],[14,2138],[2140,2113,2141,2142],{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"intervention":2973,"totalTrials":128,"cells":2974},"Alendronate",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2991,"NA":2993},{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[],{"trials":2982,"activeCount":99},[2983],{"nctId":2984,"briefTitle":2985,"status":105,"phases":2986,"primaryCompletion":2987,"completion":2987,"start":2188,"enrollment":2988,"conditions":2989,"interventions":2990},"NCT02230332","Alendronate to Prevent Loss of Bronchoprotection in Asthma",[88,89],"2016-09",78,[14],[2973],{"trials":2992,"activeCount":99},[],{"trials":2994,"activeCount":99},[],{"intervention":1093,"totalTrials":128,"cells":2996},{"EARLY_PHASE1":2997,"PHASE1":2999,"PHASE2":3001,"PHASE3":3003,"PHASE4":3009,"NA":3011},{"trials":2998,"activeCount":99},[],{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":99},[3005],{"nctId":1082,"briefTitle":1083,"status":147,"phases":3006,"primaryCompletion":1085,"completion":1086,"start":1087,"enrollment":1088,"conditions":3007,"interventions":3008},[89],[1090,1091],[1076,1057,1093],{"trials":3010,"activeCount":99},[],{"trials":3012,"activeCount":99},[],{"intervention":3014,"totalTrials":128,"cells":3015},"Mometasone 220mcg BID",{"EARLY_PHASE1":3016,"PHASE1":3018,"PHASE2":3020,"PHASE3":3022,"PHASE4":3033,"NA":3035},{"trials":3017,"activeCount":99},[],{"trials":3019,"activeCount":99},[],{"trials":3021,"activeCount":99},[],{"trials":3023,"activeCount":99},[3024],{"nctId":3025,"briefTitle":3026,"status":105,"phases":3027,"primaryCompletion":3028,"completion":3028,"start":2231,"enrollment":3029,"conditions":3030,"interventions":3031},"NCT02066298","Steroids In Eosinophil Negative Asthma",[89],"2018-05",295,[14],[3014,3032],"Tiotropium Respimat 5mcg QD",{"trials":3034,"activeCount":99},[],{"trials":3036,"activeCount":99},[],{"intervention":3032,"totalTrials":128,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3043,"PHASE3":3045,"PHASE4":3051,"NA":3053},{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[],{"trials":3044,"activeCount":99},[],{"trials":3046,"activeCount":99},[3047],{"nctId":3025,"briefTitle":3026,"status":105,"phases":3048,"primaryCompletion":3028,"completion":3028,"start":2231,"enrollment":3029,"conditions":3049,"interventions":3050},[89],[14],[3014,3032],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[],{"intervention":3056,"totalTrials":128,"cells":3057},"IC-Green KIT",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3062,"PHASE3":3064,"PHASE4":3078,"NA":3080},{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[],{"trials":3063,"activeCount":99},[],{"trials":3065,"activeCount":99},[3066],{"nctId":3067,"briefTitle":3068,"status":105,"phases":3069,"primaryCompletion":3070,"completion":3071,"start":3072,"enrollment":3073,"conditions":3074,"interventions":3077},"NCT03294330","SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Breast Cancer",[89],"2021-09-17","2021-11-02","2017-10-11",35,[3075,3076,17],"Sentinel Lymph Node","Melanoma (Skin)",[3056],{"trials":3079,"activeCount":99},[],{"trials":3081,"activeCount":99},[],{"intervention":380,"totalTrials":747,"cells":3083},{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3101,"PHASE3":3111,"PHASE4":3113,"NA":3115},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[3088,3092],{"nctId":522,"briefTitle":523,"status":105,"phases":3089,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":3090,"interventions":3091},[87],[375,376,377],[379,380,531,383,515,384],{"nctId":3093,"briefTitle":3094,"status":366,"phases":3095,"start":3096,"enrollment":15,"conditions":3097,"interventions":3098},"NCT00436761","Busulfan, Melphalan, and Antithymocyte Globulin Followed By Umbilical Cord Blood Transplant in Treating Young Patients With Refractory or Relapsed Malignant Solid Tumors",[87],"2004-05",[377],[379,3099,3100,380,531,383,384],"graft-versus-tumor induction therapy","sargramostim",{"trials":3102,"activeCount":99},[3103,3107],{"nctId":328,"briefTitle":329,"status":147,"phases":3104,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":3105,"interventions":3106},[88],[335],[337,310,338,293,339,340,341],{"nctId":364,"briefTitle":365,"status":366,"phases":3108,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":3109,"interventions":3110},[88],[370,371,372,373,374,375,376,377],[379,380,381,382,383,384],{"trials":3112,"activeCount":99},[],{"trials":3114,"activeCount":99},[],{"trials":3116,"activeCount":99},[],{"intervention":3118,"totalTrials":1058,"cells":3119},"Opioid Growth Factor",{"EARLY_PHASE1":3120,"PHASE1":3122,"PHASE2":3133,"PHASE3":3152,"PHASE4":3154,"NA":3156},{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[3124],{"nctId":3125,"briefTitle":3126,"status":147,"phases":3127,"primaryCompletion":2159,"completion":3128,"start":1485,"enrollment":747,"conditions":3129,"interventions":3131},"NCT00783172","Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer",[87],"2011-10",[3130],"Pancreatic Cancer",[3132,3118],"Gemcitabine",{"trials":3134,"activeCount":99},[3135,3142],{"nctId":3136,"briefTitle":3137,"status":147,"phases":3138,"primaryCompletion":1071,"completion":1071,"start":2745,"enrollment":294,"conditions":3139,"interventions":3141},"NCT00982696","Treatment of Advanced Head and Neck Cancer",[88],[3140],"Carcinoma, Squamous Cell of Head and Neck",[3118],{"nctId":3143,"briefTitle":3144,"status":105,"phases":3145,"primaryCompletion":3146,"completion":2067,"start":3147,"enrollment":306,"conditions":3148,"interventions":3149},"NCT00109941","Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery",[88],"2007-09","2003-10",[3130],[3150,3151],"opioid growth factor","metenkephalin, OGF-opioid growth factor",{"trials":3153,"activeCount":99},[],{"trials":3155,"activeCount":99},[],{"trials":3157,"activeCount":99},[],{"intervention":379,"totalTrials":1058,"cells":3159},{"EARLY_PHASE1":3160,"PHASE1":3162,"PHASE2":3172,"PHASE3":3178,"PHASE4":3180,"NA":3182},{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[3164,3168],{"nctId":522,"briefTitle":523,"status":105,"phases":3165,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":3166,"interventions":3167},[87],[375,376,377],[379,380,531,383,515,384],{"nctId":3093,"briefTitle":3094,"status":366,"phases":3169,"start":3096,"enrollment":15,"conditions":3170,"interventions":3171},[87],[377],[379,3099,3100,380,531,383,384],{"trials":3173,"activeCount":99},[3174],{"nctId":364,"briefTitle":365,"status":366,"phases":3175,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":3176,"interventions":3177},[88],[370,371,372,373,374,375,376,377],[379,380,381,382,383,384],{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"trials":3183,"activeCount":99},[],{"intervention":383,"totalTrials":1058,"cells":3185},{"EARLY_PHASE1":3186,"PHASE1":3188,"PHASE2":3198,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3187,"activeCount":99},[],{"trials":3189,"activeCount":99},[3190,3194],{"nctId":522,"briefTitle":523,"status":105,"phases":3191,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":3192,"interventions":3193},[87],[375,376,377],[379,380,531,383,515,384],{"nctId":3093,"briefTitle":3094,"status":366,"phases":3195,"start":3096,"enrollment":15,"conditions":3196,"interventions":3197},[87],[377],[379,3099,3100,380,531,383,384],{"trials":3199,"activeCount":99},[3200],{"nctId":364,"briefTitle":365,"status":366,"phases":3201,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":3202,"interventions":3203},[88],[370,371,372,373,374,375,376,377],[379,380,381,382,383,384],{"trials":3205,"activeCount":99},[],{"trials":3207,"activeCount":99},[],{"trials":3209,"activeCount":99},[],{"intervention":384,"totalTrials":1058,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3224,"PHASE3":3230,"PHASE4":3232,"NA":3234},{"trials":3213,"activeCount":99},[],{"trials":3215,"activeCount":99},[3216,3220],{"nctId":522,"briefTitle":523,"status":105,"phases":3217,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":3218,"interventions":3219},[87],[375,376,377],[379,380,531,383,515,384],{"nctId":3093,"briefTitle":3094,"status":366,"phases":3221,"start":3096,"enrollment":15,"conditions":3222,"interventions":3223},[87],[377],[379,3099,3100,380,531,383,384],{"trials":3225,"activeCount":99},[3226],{"nctId":364,"briefTitle":365,"status":366,"phases":3227,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":3228,"interventions":3229},[88],[370,371,372,373,374,375,376,377],[379,380,381,382,383,384],{"trials":3231,"activeCount":99},[],{"trials":3233,"activeCount":99},[],{"trials":3235,"activeCount":99},[],{"intervention":337,"totalTrials":95,"cells":3237},{"EARLY_PHASE1":3238,"PHASE1":3240,"PHASE2":3246,"PHASE3":3252,"PHASE4":3254,"NA":3256},{"trials":3239,"activeCount":99},[],{"trials":3241,"activeCount":99},[3242],{"nctId":493,"briefTitle":494,"status":147,"phases":3243,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":3244,"interventions":3245},[87],[372],[337,501,360],{"trials":3247,"activeCount":99},[3248],{"nctId":328,"briefTitle":329,"status":147,"phases":3249,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":3250,"interventions":3251},[88],[335],[337,310,338,293,339,340,341],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"trials":3257,"activeCount":99},[],{"intervention":382,"totalTrials":95,"cells":3259},{"EARLY_PHASE1":3260,"PHASE1":3262,"PHASE2":3273,"PHASE3":3279,"PHASE4":3281,"NA":3283},{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[3264],{"nctId":3265,"briefTitle":3266,"status":366,"phases":3267,"start":3268,"conditions":3269,"interventions":3270},"NCT00006100","Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma",[87],"2000-04",[373],[3271,3272,382],"aldesleukin","allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes",{"trials":3274,"activeCount":99},[3275],{"nctId":364,"briefTitle":365,"status":366,"phases":3276,"primaryCompletion":107,"start":368,"enrollment":306,"conditions":3277,"interventions":3278},[88],[370,371,372,373,374,375,376,377],[379,380,381,382,383,384],{"trials":3280,"activeCount":99},[],{"trials":3282,"activeCount":99},[],{"trials":3284,"activeCount":99},[],{"intervention":310,"totalTrials":95,"cells":3286},{"EARLY_PHASE1":3287,"PHASE1":3289,"PHASE2":3295,"PHASE3":3301,"PHASE4":3303,"NA":3305},{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[3291],{"nctId":301,"briefTitle":302,"status":147,"phases":3292,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":3293,"interventions":3294},[87],[308],[310,293,311],{"trials":3296,"activeCount":99},[3297],{"nctId":328,"briefTitle":329,"status":147,"phases":3298,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":3299,"interventions":3300},[88],[335],[337,310,338,293,339,340,341],{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":99},[],{"intervention":3308,"totalTrials":128,"cells":3309},"Prednisone",{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3326,"PHASE4":3328,"NA":3330},{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[3316],{"nctId":3317,"briefTitle":3318,"status":1120,"phases":3319,"primaryCompletion":3320,"completion":3320,"start":3321,"enrollment":99,"conditions":3322,"interventions":3325},"NCT00893048","The Use of Oral Steroids in the Treatment of Cellulitis",[88],"2010-08-31","2010-01-15",[3323,3324],"Cellulitis","Erysipelas",[3308],{"trials":3327,"activeCount":99},[],{"trials":3329,"activeCount":99},[],{"trials":3331,"activeCount":99},[],{"intervention":3333,"totalTrials":128,"cells":3334},"RAD 001",{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3347,"PHASE4":3349,"NA":3351},{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[],{"trials":3340,"activeCount":99},[3341],{"nctId":3342,"briefTitle":3343,"status":147,"phases":3344,"primaryCompletion":526,"completion":526,"start":2067,"enrollment":774,"conditions":3345,"interventions":3346},"NCT00827567","Trial of RAD001 in Triple Negative Metastatic Breast Cancer",[88],[17],[3333],{"trials":3348,"activeCount":99},[],{"trials":3350,"activeCount":99},[],{"trials":3352,"activeCount":99},[],{"intervention":3354,"totalTrials":128,"cells":3355},"Clomiphene Citrate",{"EARLY_PHASE1":3356,"PHASE1":3358,"PHASE2":3360,"PHASE3":3370,"PHASE4":3372,"NA":3374},{"trials":3357,"activeCount":99},[],{"trials":3359,"activeCount":99},[],{"trials":3361,"activeCount":99},[3362],{"nctId":3363,"briefTitle":3364,"status":105,"phases":3365,"primaryCompletion":3366,"completion":3366,"start":3367,"enrollment":306,"conditions":3368,"interventions":3369},"NCT01340521","Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) Response to Low Dose Clomiphene Citrate in Normally Menstruating Fertile Women",[87,88],"1994-03","1991-03",[796],[3354],{"trials":3371,"activeCount":99},[],{"trials":3373,"activeCount":99},[],{"trials":3375,"activeCount":99},[],{"intervention":1078,"totalTrials":128,"cells":3377},{"EARLY_PHASE1":3378,"PHASE1":3380,"PHASE2":3382,"PHASE3":3388,"PHASE4":3390,"NA":3392},{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[],{"trials":3383,"activeCount":99},[3384],{"nctId":1067,"briefTitle":1068,"status":105,"phases":3385,"primaryCompletion":1070,"completion":1070,"start":1071,"enrollment":1072,"conditions":3386,"interventions":3387},[88],[1074],[1076,1077,1078],{"trials":3389,"activeCount":99},[],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"intervention":3395,"totalTrials":128,"cells":3396},"Ruxolitinib 1.5% Cream",{"EARLY_PHASE1":3397,"PHASE1":3399,"PHASE2":3401,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3398,"activeCount":99},[],{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[3403],{"nctId":3404,"briefTitle":3405,"status":147,"phases":3406,"primaryCompletion":3407,"completion":3407,"start":3408,"enrollment":774,"conditions":3409,"interventions":3411},"NCT04414514","Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment",[88],"2024-02-23","2022-10-13",[3410],"Hidradenitis Suppurativa",[3395],{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"trials":3417,"activeCount":99},[],{"intervention":3419,"totalTrials":128,"cells":3420},"Metformin",{"EARLY_PHASE1":3421,"PHASE1":3423,"PHASE2":3425,"PHASE3":3437,"PHASE4":3439,"NA":3441},{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[3427],{"nctId":3428,"briefTitle":3429,"status":105,"phases":3430,"primaryCompletion":3431,"completion":3431,"start":3432,"enrollment":3433,"conditions":3434,"interventions":3436},"NCT00151411","Lifestyle Intervention and Metformin for Women With Polycystic Ovary Syndrome (PCOS)",[88],"2008-03","2004-10",114,[3435],"Polycystic Ovary Syndrome",[3419],{"trials":3438,"activeCount":99},[],{"trials":3440,"activeCount":99},[],{"trials":3442,"activeCount":99},[],{"intervention":3444,"totalTrials":128,"cells":3445},"Clofar, Cyclophos, Alemtuzumab",{"EARLY_PHASE1":3446,"PHASE1":3448,"PHASE2":3450,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3447,"activeCount":99},[],{"trials":3449,"activeCount":99},[],{"trials":3451,"activeCount":99},[3452],{"nctId":3453,"briefTitle":3454,"status":147,"phases":3455,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":24,"conditions":3458,"interventions":3463},"NCT00626626","Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation",[87,88],"2010-01","2007-05",[372,3459,3460,373,3461,3462],"Myelodysplastic Syndrome","Chronic Myelogenous Leukemia","Hodgkin's Lymphoma","Multiple Myeloma",[3444,3464],"Clofar, Cyclophos,Alemtuzumab",{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[],{"trials":3470,"activeCount":99},[],{"intervention":3464,"totalTrials":128,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[3479],{"nctId":3453,"briefTitle":3454,"status":147,"phases":3480,"primaryCompletion":3456,"completion":3456,"start":3457,"enrollment":24,"conditions":3481,"interventions":3482},[87,88],[372,3459,3460,373,3461,3462],[3444,3464],{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[],{"trials":3488,"activeCount":99},[],{"intervention":3490,"totalTrials":128,"cells":3491},"Abemaciclib",{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3507,"PHASE4":3509,"NA":3511},{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[3498],{"nctId":3499,"briefTitle":3500,"status":147,"phases":3501,"primaryCompletion":3502,"completion":3502,"start":3503,"enrollment":747,"conditions":3504,"interventions":3506},"NCT04003896","A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma",[88],"2023-08-15","2021-09-24",[3505],"Biliary Tract Carcinoma",[3490],{"trials":3508,"activeCount":99},[],{"trials":3510,"activeCount":99},[],{"trials":3512,"activeCount":99},[],{"intervention":3514,"totalTrials":128,"cells":3515},"CCOCP",{"EARLY_PHASE1":3516,"PHASE1":3518,"PHASE2":3520,"PHASE3":3532,"PHASE4":3534,"NA":3536},{"trials":3517,"activeCount":99},[],{"trials":3519,"activeCount":99},[],{"trials":3521,"activeCount":99},[3522],{"nctId":3523,"briefTitle":3524,"status":105,"phases":3525,"primaryCompletion":496,"completion":1008,"start":3526,"enrollment":3527,"conditions":3528,"interventions":3530},"NCT00517556","Continuous Administration of Oral Contraceptive, Primary Dysmenorrhea",[87,88],"2007-08",38,[3529],"Dysmenorrhea",[3514,3531],"Traditional OCP",{"trials":3533,"activeCount":99},[],{"trials":3535,"activeCount":99},[],{"trials":3537,"activeCount":99},[],{"intervention":3531,"totalTrials":128,"cells":3539},{"EARLY_PHASE1":3540,"PHASE1":3542,"PHASE2":3544,"PHASE3":3550,"PHASE4":3552,"NA":3554},{"trials":3541,"activeCount":99},[],{"trials":3543,"activeCount":99},[],{"trials":3545,"activeCount":99},[3546],{"nctId":3523,"briefTitle":3524,"status":105,"phases":3547,"primaryCompletion":496,"completion":1008,"start":3526,"enrollment":3527,"conditions":3548,"interventions":3549},[87,88],[3529],[3514,3531],{"trials":3551,"activeCount":99},[],{"trials":3553,"activeCount":99},[],{"trials":3555,"activeCount":99},[],{"intervention":3557,"totalTrials":128,"cells":3558},"Pioglitazone 45 mg",{"EARLY_PHASE1":3559,"PHASE1":3561,"PHASE2":3563,"PHASE3":3576,"PHASE4":3578,"NA":3580},{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[],{"trials":3564,"activeCount":99},[3565],{"nctId":3566,"briefTitle":3567,"status":147,"phases":3568,"primaryCompletion":3569,"completion":3569,"start":3570,"enrollment":128,"conditions":3571,"interventions":3575},"NCT04123067","Pioglitazone Treatment for Hyperglycemic Acute Ischemic Stroke",[87,88],"2021-04-07","2020-09-01",[3572,3573,3574],"Stroke, Acute","Hyperglycemia","Diabetes",[3557],{"trials":3577,"activeCount":99},[],{"trials":3579,"activeCount":99},[],{"trials":3581,"activeCount":99},[],{"intervention":3583,"totalTrials":128,"cells":3584},"Eicosapentaenoic Acid",{"EARLY_PHASE1":3585,"PHASE1":3587,"PHASE2":3589,"PHASE3":3601,"PHASE4":3603,"NA":3605},{"trials":3586,"activeCount":99},[],{"trials":3588,"activeCount":99},[],{"trials":3590,"activeCount":99},[3591],{"nctId":3592,"briefTitle":3593,"status":147,"phases":3594,"primaryCompletion":3595,"completion":3595,"start":3596,"enrollment":128,"conditions":3597,"interventions":3599},"NCT04006847","Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia",[87,88],"2021-05-21","2020-09-14",[3598],"Chronic Myeloid Leukemia, Chronic Phase",[3583,3600],"Tyrosine kinase inhibitor",{"trials":3602,"activeCount":99},[],{"trials":3604,"activeCount":99},[],{"trials":3606,"activeCount":99},[],{"intervention":3600,"totalTrials":128,"cells":3608},{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3619,"PHASE4":3621,"NA":3623},{"trials":3610,"activeCount":99},[],{"trials":3612,"activeCount":99},[],{"trials":3614,"activeCount":99},[3615],{"nctId":3592,"briefTitle":3593,"status":147,"phases":3616,"primaryCompletion":3595,"completion":3595,"start":3596,"enrollment":128,"conditions":3617,"interventions":3618},[87,88],[3598],[3583,3600],{"trials":3620,"activeCount":99},[],{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[],{"intervention":3626,"totalTrials":128,"cells":3627},"Oncaspar, Doxil, Decadron",{"EARLY_PHASE1":3628,"PHASE1":3630,"PHASE2":3632,"PHASE3":3645,"PHASE4":3647,"NA":3649},{"trials":3629,"activeCount":99},[],{"trials":3631,"activeCount":99},[],{"trials":3633,"activeCount":99},[3634],{"nctId":3635,"briefTitle":3636,"status":147,"phases":3637,"primaryCompletion":3638,"completion":3639,"start":497,"enrollment":3640,"conditions":3641,"interventions":3644},"NCT00837200","Oncaspar\u002FDoxil\u002FDecadron in Patients With Refractory Lymphoid Malignancies",[88],"2011-01","2013-10",13,[3642,3643,3462],"Non-hodgkins Lymphoma","Hodgkins Lymphoma",[3626],{"trials":3646,"activeCount":99},[],{"trials":3648,"activeCount":99},[],{"trials":3650,"activeCount":99},[],{"intervention":3652,"totalTrials":128,"cells":3653},"Pasireotide",{"EARLY_PHASE1":3654,"PHASE1":3656,"PHASE2":3658,"PHASE3":3669,"PHASE4":3671,"NA":3673},{"trials":3655,"activeCount":99},[],{"trials":3657,"activeCount":99},[],{"trials":3659,"activeCount":99},[3660],{"nctId":3661,"briefTitle":3662,"status":1120,"phases":3663,"primaryCompletion":107,"completion":3664,"start":3665,"enrollment":99,"conditions":3666,"interventions":3667},"NCT01234974","IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus",[88],"2013-12","2010-12",[3462],[3652,3668],"Everolimus",{"trials":3670,"activeCount":99},[],{"trials":3672,"activeCount":99},[],{"trials":3674,"activeCount":99},[],{"intervention":3668,"totalTrials":128,"cells":3676},{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3687,"PHASE4":3689,"NA":3691},{"trials":3678,"activeCount":99},[],{"trials":3680,"activeCount":99},[],{"trials":3682,"activeCount":99},[3683],{"nctId":3661,"briefTitle":3662,"status":1120,"phases":3684,"primaryCompletion":107,"completion":3664,"start":3665,"enrollment":99,"conditions":3685,"interventions":3686},[88],[3462],[3652,3668],{"trials":3688,"activeCount":99},[],{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[],{"intervention":3694,"totalTrials":128,"cells":3695},"Inositol",{"EARLY_PHASE1":3696,"PHASE1":3698,"PHASE2":3700,"PHASE3":3716,"PHASE4":3718,"NA":3720},{"trials":3697,"activeCount":99},[],{"trials":3699,"activeCount":99},[],{"trials":3701,"activeCount":99},[3702],{"nctId":3703,"briefTitle":3704,"status":105,"phases":3705,"primaryCompletion":3706,"completion":3706,"start":3707,"enrollment":3708,"conditions":3709,"interventions":3715},"NCT03864068","Inositol Supplementation to Treat PCOS (INSUPP-PCOS)",[88],"2025-12-10","2020-01-24",154,[3435,3710,3711,3712,3713,3714],"Anovulation","Hyperandrogenism","Insulin Resistance","Glucose Intolerance","Metabolic Complication",[3694],{"trials":3717,"activeCount":99},[],{"trials":3719,"activeCount":99},[],{"trials":3721,"activeCount":99},[],{"intervention":3723,"totalTrials":128,"cells":3724},"Cetuximab",{"EARLY_PHASE1":3725,"PHASE1":3727,"PHASE2":3729,"PHASE3":3740,"PHASE4":3742,"NA":3744},{"trials":3726,"activeCount":99},[],{"trials":3728,"activeCount":99},[],{"trials":3730,"activeCount":99},[3731],{"nctId":3732,"briefTitle":3733,"status":1120,"phases":3734,"primaryCompletion":3735,"completion":3735,"start":3736,"enrollment":99,"conditions":3737,"interventions":3739},"NCT00934518","Image Guided Intensity Modulated Reirradiation (IG-IMRT) With Cetuximab for Locoregionally Confined Recurrent Head and Neck Squamous Cell Carcinoma",[88],"2011-07","2009-07",[3738],"Squamous Cell Cancer of the Head and Neck",[3723],{"trials":3741,"activeCount":99},[],{"trials":3743,"activeCount":99},[],{"trials":3745,"activeCount":99},[],{"intervention":3747,"totalTrials":128,"cells":3748},"Liraglutide Pen Injector",{"EARLY_PHASE1":3749,"PHASE1":3751,"PHASE2":3753,"PHASE3":3766,"PHASE4":3768,"NA":3770},{"trials":3750,"activeCount":99},[],{"trials":3752,"activeCount":99},[],{"trials":3754,"activeCount":99},[3755],{"nctId":3756,"briefTitle":3757,"status":105,"phases":3758,"primaryCompletion":3759,"completion":3759,"start":3760,"enrollment":3761,"conditions":3762,"interventions":3765},"NCT04199728","Use of a GLP-1R Agonist to Treat Opioid Use Disorder",[87,88],"2023-09-13","2021-10-18",27,[3763,3764],"Opiate Substitution Treatment","Opioid-Related Disorders",[3747],{"trials":3767,"activeCount":99},[],{"trials":3769,"activeCount":99},[],{"trials":3771,"activeCount":99},[],{"intervention":3773,"totalTrials":128,"cells":3774},"Dexmedetomidine",{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3792,"PHASE4":3794,"NA":3796},{"trials":3776,"activeCount":99},[],{"trials":3778,"activeCount":99},[],{"trials":3780,"activeCount":99},[3781],{"nctId":3782,"briefTitle":3783,"status":147,"phases":3784,"primaryCompletion":3785,"completion":3786,"start":3787,"enrollment":1009,"conditions":3788,"interventions":3790},"NCT01505933","Airway Dimension Study in Children Undergoing MRI Sedated With Propofol and Dexmedetomidine",[88],"2017-12-01","2019-04-30","2012-02",[3789],"Airway Remodeling",[3773,3791],"propofol",{"trials":3793,"activeCount":99},[],{"trials":3795,"activeCount":99},[],{"trials":3797,"activeCount":99},[],{"intervention":3799,"totalTrials":128,"cells":3800},"Sildenafil Citrate",{"EARLY_PHASE1":3801,"PHASE1":3803,"PHASE2":3805,"PHASE3":3815,"PHASE4":3817,"NA":3819},{"trials":3802,"activeCount":99},[],{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[3807],{"nctId":3808,"briefTitle":3809,"status":105,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3457,"enrollment":306,"conditions":3813,"interventions":3814},"NCT00123162","Viagra in the Treatment of Primary Dysmenorrhea",[87,88],"2011-06","2011-08",[3529],[3799],{"trials":3816,"activeCount":99},[],{"trials":3818,"activeCount":99},[],{"trials":3820,"activeCount":99},[],{"intervention":3151,"totalTrials":128,"cells":3822},{"EARLY_PHASE1":3823,"PHASE1":3825,"PHASE2":3827,"PHASE3":3833,"PHASE4":3835,"NA":3837},{"trials":3824,"activeCount":99},[],{"trials":3826,"activeCount":99},[],{"trials":3828,"activeCount":99},[3829],{"nctId":3143,"briefTitle":3144,"status":105,"phases":3830,"primaryCompletion":3146,"completion":2067,"start":3147,"enrollment":306,"conditions":3831,"interventions":3832},[88],[3130],[3150,3151],{"trials":3834,"activeCount":99},[],{"trials":3836,"activeCount":99},[],{"trials":3838,"activeCount":99},[],{"intervention":3840,"totalTrials":128,"cells":3841},"Naltrexone-HCl",{"EARLY_PHASE1":3842,"PHASE1":3844,"PHASE2":3846,"PHASE3":3857,"PHASE4":3859,"NA":3861},{"trials":3843,"activeCount":99},[],{"trials":3845,"activeCount":99},[],{"trials":3847,"activeCount":99},[3848],{"nctId":3849,"briefTitle":3850,"status":105,"phases":3851,"primaryCompletion":3852,"completion":3852,"start":3853,"enrollment":124,"conditions":3854,"interventions":3856},"NCT00663117","The Effects of Naltrexone on Active Crohn's Disease",[88],"2009-10","2006-09",[3855,1902],"Inflammation",[3840],{"trials":3858,"activeCount":99},[],{"trials":3860,"activeCount":99},[],{"trials":3862,"activeCount":99},[],{"intervention":3864,"totalTrials":128,"cells":3865},"Orlistat\u002FMeal Replacement\u002FLifestyle Modification",{"EARLY_PHASE1":3866,"PHASE1":3868,"PHASE2":3870,"PHASE3":3883,"PHASE4":3885,"NA":3887},{"trials":3867,"activeCount":99},[],{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[3872],{"nctId":3873,"briefTitle":3874,"status":105,"phases":3875,"primaryCompletion":3876,"completion":3876,"start":3877,"enrollment":3878,"conditions":3879,"interventions":3880},"NCT00704912","Treatment of Hyperandrogenism Versus Insulin Resistance in Infertile Polycystic Ovary Syndrome (PCOS) Women",[88],"2014-03","2008-09",217,[3435],[3864,3881,3882],"Loestrin 1\u002F20","Combination of treatments",{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":99},[],{"trials":3888,"activeCount":99},[],{"intervention":3881,"totalTrials":128,"cells":3890},{"EARLY_PHASE1":3891,"PHASE1":3893,"PHASE2":3895,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3892,"activeCount":99},[],{"trials":3894,"activeCount":99},[],{"trials":3896,"activeCount":99},[3897],{"nctId":3873,"briefTitle":3874,"status":105,"phases":3898,"primaryCompletion":3876,"completion":3876,"start":3877,"enrollment":3878,"conditions":3899,"interventions":3900},[88],[3435],[3864,3881,3882],{"trials":3902,"activeCount":99},[],{"trials":3904,"activeCount":99},[],{"trials":3906,"activeCount":99},[],{"intervention":3882,"totalTrials":128,"cells":3908},{"EARLY_PHASE1":3909,"PHASE1":3911,"PHASE2":3913,"PHASE3":3919,"PHASE4":3921,"NA":3923},{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[3915],{"nctId":3873,"briefTitle":3874,"status":105,"phases":3916,"primaryCompletion":3876,"completion":3876,"start":3877,"enrollment":3878,"conditions":3917,"interventions":3918},[88],[3435],[3864,3881,3882],{"trials":3920,"activeCount":99},[],{"trials":3922,"activeCount":99},[],{"trials":3924,"activeCount":99},[],{"intervention":3926,"totalTrials":128,"cells":3927},"Pevonedistat",{"EARLY_PHASE1":3928,"PHASE1":3930,"PHASE2":3932,"PHASE3":3944,"PHASE4":3946,"NA":3948},{"trials":3929,"activeCount":99},[],{"trials":3931,"activeCount":99},[],{"trials":3933,"activeCount":99},[3934],{"nctId":3935,"briefTitle":3936,"status":147,"phases":3937,"primaryCompletion":3938,"completion":3938,"start":3939,"enrollment":1058,"conditions":3940,"interventions":3942},"NCT03709576","Pevonedistat and Azacitidine as Maintenance Therapy After Allogeneic Stem Cell Transplantation for Non-Remission AML",[88],"2019-07-22","2018-07-18",[3941],"Acute Myeloid Leukemia (AML)",[3926,3943],"Azacitidine",{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"intervention":3943,"totalTrials":128,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3962,"PHASE4":3964,"NA":3966},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[3958],{"nctId":3935,"briefTitle":3936,"status":147,"phases":3959,"primaryCompletion":3938,"completion":3938,"start":3939,"enrollment":1058,"conditions":3960,"interventions":3961},[88],[3941],[3926,3943],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"intervention":479,"totalTrials":128,"cells":3969},{"EARLY_PHASE1":3970,"PHASE1":3972,"PHASE2":3974,"PHASE3":3980,"PHASE4":3982,"NA":3984},{"trials":3971,"activeCount":99},[],{"trials":3973,"activeCount":99},[],{"trials":3975,"activeCount":99},[3976],{"nctId":469,"briefTitle":470,"status":105,"phases":3977,"primaryCompletion":472,"completion":473,"start":474,"enrollment":475,"conditions":3978,"interventions":3979},[88],[477],[479,412],{"trials":3981,"activeCount":99},[],{"trials":3983,"activeCount":99},[],{"trials":3985,"activeCount":99},[],{"intervention":3987,"totalTrials":128,"cells":3988},"Lipitor",{"EARLY_PHASE1":3989,"PHASE1":3991,"PHASE2":3993,"PHASE3":4001,"PHASE4":4003,"NA":4005},{"trials":3990,"activeCount":99},[],{"trials":3992,"activeCount":99},[],{"trials":3994,"activeCount":99},[3995],{"nctId":3996,"briefTitle":3997,"status":105,"phases":3998,"primaryCompletion":2159,"completion":2159,"start":2746,"enrollment":15,"conditions":3999,"interventions":4000},"NCT00529542","A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol",[88],[3435],[3987],{"trials":4002,"activeCount":99},[],{"trials":4004,"activeCount":99},[],{"trials":4006,"activeCount":99},[],{"intervention":339,"totalTrials":128,"cells":4008},{"EARLY_PHASE1":4009,"PHASE1":4011,"PHASE2":4013,"PHASE3":4019,"PHASE4":4021,"NA":4023},{"trials":4010,"activeCount":99},[],{"trials":4012,"activeCount":99},[],{"trials":4014,"activeCount":99},[4015],{"nctId":328,"briefTitle":329,"status":147,"phases":4016,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":4017,"interventions":4018},[88],[335],[337,310,338,293,339,340,341],{"trials":4020,"activeCount":99},[],{"trials":4022,"activeCount":99},[],{"trials":4024,"activeCount":99},[],{"intervention":340,"totalTrials":128,"cells":4026},{"EARLY_PHASE1":4027,"PHASE1":4029,"PHASE2":4031,"PHASE3":4037,"PHASE4":4039,"NA":4041},{"trials":4028,"activeCount":99},[],{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[4033],{"nctId":328,"briefTitle":329,"status":147,"phases":4034,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":4035,"interventions":4036},[88],[335],[337,310,338,293,339,340,341],{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[],{"trials":4042,"activeCount":99},[],{"intervention":341,"totalTrials":128,"cells":4044},{"EARLY_PHASE1":4045,"PHASE1":4047,"PHASE2":4049,"PHASE3":4055,"PHASE4":4057,"NA":4059},{"trials":4046,"activeCount":99},[],{"trials":4048,"activeCount":99},[],{"trials":4050,"activeCount":99},[4051],{"nctId":328,"briefTitle":329,"status":147,"phases":4052,"primaryCompletion":331,"completion":332,"start":333,"enrollment":95,"conditions":4053,"interventions":4054},[88],[335],[337,310,338,293,339,340,341],{"trials":4056,"activeCount":99},[],{"trials":4058,"activeCount":99},[],{"trials":4060,"activeCount":99},[],{"intervention":4062,"totalTrials":128,"cells":4063},"Vorinostat, Carboplatin, Etoposide",{"EARLY_PHASE1":4064,"PHASE1":4066,"PHASE2":4068,"PHASE3":4078,"PHASE4":4080,"NA":4082},{"trials":4065,"activeCount":99},[],{"trials":4067,"activeCount":99},[],{"trials":4069,"activeCount":99},[4070],{"nctId":4071,"briefTitle":4072,"status":147,"phases":4073,"primaryCompletion":4074,"completion":4074,"start":3877,"enrollment":24,"conditions":4075,"interventions":4077},"NCT00702962","Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer",[87,88],"2012-07",[4076],"Small Cell Lung Cancer",[4062],{"trials":4079,"activeCount":99},[],{"trials":4081,"activeCount":99},[],{"trials":4083,"activeCount":99},[],{"intervention":4085,"totalTrials":128,"cells":4086},"Sunitinib",{"EARLY_PHASE1":4087,"PHASE1":4089,"PHASE2":4091,"PHASE3":4100,"PHASE4":4102,"NA":4104},{"trials":4088,"activeCount":99},[],{"trials":4090,"activeCount":99},[],{"trials":4092,"activeCount":99},[4093],{"nctId":4094,"briefTitle":4095,"status":147,"phases":4096,"primaryCompletion":1008,"completion":1008,"start":3457,"enrollment":747,"conditions":4097,"interventions":4099},"NCT00796861","Trial of Sunitinib for Refractory Malignant Ascites",[88],[4098],"Ascites",[4085],{"trials":4101,"activeCount":99},[],{"trials":4103,"activeCount":99},[],{"trials":4105,"activeCount":99},[],{"intervention":4107,"totalTrials":128,"cells":4108},"Hydroxychloroquine",{"EARLY_PHASE1":4109,"PHASE1":4111,"PHASE2":4113,"PHASE3":4124,"PHASE4":4126,"NA":4128},{"trials":4110,"activeCount":99},[],{"trials":4112,"activeCount":99},[],{"trials":4114,"activeCount":99},[4115],{"nctId":4116,"briefTitle":4117,"status":105,"phases":4118,"primaryCompletion":149,"completion":149,"start":4119,"enrollment":4120,"conditions":4121,"interventions":4123},"NCT03030118","Study of Anti-Malarials in Incomplete Lupus Erythematosus",[88],"2017-12-28",187,[4122],"Systemic Lupus Erythematosus",[4107],{"trials":4125,"activeCount":99},[],{"trials":4127,"activeCount":99},[],{"trials":4129,"activeCount":99},[],{"intervention":4131,"totalTrials":128,"cells":4132},"granisetron",{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4146,"PHASE4":4148,"NA":4150},{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[],{"trials":4138,"activeCount":99},[4139],{"nctId":4140,"briefTitle":4141,"status":105,"phases":4142,"primaryCompletion":4143,"completion":4143,"start":1610,"enrollment":1051,"conditions":4144,"interventions":4145},"NCT02457195","Granisetron Transdermal Patch for Prevention of Postoperative Nausea and Vomiting",[88],"2018-02-19",[1288],[4131],{"trials":4147,"activeCount":99},[],{"trials":4149,"activeCount":99},[],{"trials":4151,"activeCount":99},[],{"intervention":4153,"totalTrials":95,"cells":4154},"Bortezomib",{"EARLY_PHASE1":4155,"PHASE1":4157,"PHASE2":4182,"PHASE3":4184,"PHASE4":4186,"NA":4188},{"trials":4156,"activeCount":99},[],{"trials":4158,"activeCount":99},[4159,4169],{"nctId":4160,"briefTitle":4161,"status":147,"phases":4162,"primaryCompletion":2126,"completion":2126,"start":4163,"enrollment":774,"conditions":4164,"interventions":4166},"NCT00714246","Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer",[87],"2008-10",[4165],"Non Small Cell Lung Cancer",[4153,4167,4168],"Carboplatin","Docetaxel",{"nctId":4170,"briefTitle":4171,"status":366,"phases":4172,"primaryCompletion":4173,"completion":4174,"start":4175,"enrollment":3640,"conditions":4176,"interventions":4178},"NCT01439750","Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)",[87],"2018-08","2020-08","2012-05",[4177],"Mantle Cell Lymphoma",[4179,4180,4181],"Rituximab","bortezomib","Cladribine",{"trials":4183,"activeCount":99},[],{"trials":4185,"activeCount":99},[],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"intervention":3271,"totalTrials":95,"cells":4191},{"EARLY_PHASE1":4192,"PHASE1":4194,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4193,"activeCount":99},[],{"trials":4195,"activeCount":99},[4196,4206],{"nctId":4197,"briefTitle":4198,"status":366,"phases":4199,"primaryCompletion":4200,"start":4201,"enrollment":528,"conditions":4202,"interventions":4203},"NCT00101309","Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma",[87],"2007-11","2004-11",[375,376],[3271,4204,4205],"autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine","therapeutic autologous lymphocytes",{"nctId":3265,"briefTitle":3266,"status":366,"phases":4207,"start":3268,"conditions":4208,"interventions":4209},[87],[373],[3271,3272,382],{"trials":4211,"activeCount":99},[],{"trials":4213,"activeCount":99},[],{"trials":4215,"activeCount":99},[],{"trials":4217,"activeCount":99},[],{"intervention":311,"totalTrials":95,"cells":4219},{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4237,"PHASE3":4239,"PHASE4":4241,"NA":4243},{"trials":4221,"activeCount":99},[],{"trials":4223,"activeCount":99},[4224,4228],{"nctId":301,"briefTitle":302,"status":147,"phases":4225,"primaryCompletion":304,"completion":304,"start":305,"enrollment":306,"conditions":4226,"interventions":4227},[87],[308],[310,293,311],{"nctId":4229,"briefTitle":4230,"status":105,"phases":4231,"primaryCompletion":4232,"completion":4232,"start":4233,"enrollment":95,"conditions":4234,"interventions":4236},"NCT00673868","Cytomegalovirus (CMV) Specific Cytotoxic T Lymphocytes (CTL) When Used for Prophylaxis Against CMV in Recipients of Allogeneic, T Cell Depleted Stem Cell Transplants",[87],"2008-08-06","2007-10",[4235],"Cytomegalovirus Infections",[311],{"trials":4238,"activeCount":99},[],{"trials":4240,"activeCount":99},[],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[],{"intervention":531,"totalTrials":95,"cells":4246},{"EARLY_PHASE1":4247,"PHASE1":4249,"PHASE2":4259,"PHASE3":4261,"PHASE4":4263,"NA":4265},{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[4251,4255],{"nctId":522,"briefTitle":523,"status":105,"phases":4252,"primaryCompletion":525,"completion":526,"start":527,"enrollment":528,"conditions":4253,"interventions":4254},[87],[375,376,377],[379,380,531,383,515,384],{"nctId":3093,"briefTitle":3094,"status":366,"phases":4256,"start":3096,"enrollment":15,"conditions":4257,"interventions":4258},[87],[377],[379,3099,3100,380,531,383,384],{"trials":4260,"activeCount":99},[],{"trials":4262,"activeCount":99},[],{"trials":4264,"activeCount":99},[],{"trials":4266,"activeCount":99},[],{"intervention":4268,"totalTrials":128,"cells":4269},"Ketamine plus Magnesium sulfate",{"EARLY_PHASE1":4270,"PHASE1":4272,"PHASE2":4282,"PHASE3":4284,"PHASE4":4286,"NA":4288},{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[4274],{"nctId":4275,"briefTitle":4276,"status":147,"phases":4277,"primaryCompletion":4278,"completion":4278,"start":2806,"enrollment":15,"conditions":4279,"interventions":4281},"NCT02940509","Ketamine and Magnesium in Post-operative Pain Control in Patients Treated With Opioids",[87],"2018-02-27",[4280],"Chronic Pain",[4268],{"trials":4283,"activeCount":99},[],{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[],{"trials":4289,"activeCount":99},[],{"intervention":4291,"totalTrials":128,"cells":4292},"Avelumab",{"EARLY_PHASE1":4293,"PHASE1":4295,"PHASE2":4305,"PHASE3":4307,"PHASE4":4309,"NA":4311},{"trials":4294,"activeCount":99},[],{"trials":4296,"activeCount":99},[4297],{"nctId":4298,"briefTitle":4299,"status":147,"phases":4300,"primaryCompletion":4301,"completion":4301,"start":4302,"enrollment":29,"conditions":4303,"interventions":4304},"NCT03395873","Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive Chemotherapy",[87],"2019-05-15","2018-01-29",[335],[4291],{"trials":4306,"activeCount":99},[],{"trials":4308,"activeCount":99},[],{"trials":4310,"activeCount":99},[],{"trials":4312,"activeCount":99},[],{"intervention":4314,"totalTrials":128,"cells":4315},"Sargramostim 0.04 mcg\u002Fkg\u002Fdose",{"EARLY_PHASE1":4316,"PHASE1":4318,"PHASE2":4332,"PHASE3":4334,"PHASE4":4336,"NA":4338},{"trials":4317,"activeCount":99},[],{"trials":4319,"activeCount":99},[4320],{"nctId":4321,"briefTitle":4322,"status":1120,"phases":4323,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":99,"conditions":4326,"interventions":4329},"NCT02601365","Inhaled GM-CSF for Respiratory Virus-Associated Severe Pneumonia",[87],"2019-05","2019-03",[4327,2390,4328],"Acute Respiratory Distress Syndrome","Respiratory Virus Infection",[4314,4330,4331],"Sargramostim 0.2mcg\u002Fkg\u002Fdose","Sargramostim 1 mcg\u002Fkg\u002Fdose",{"trials":4333,"activeCount":99},[],{"trials":4335,"activeCount":99},[],{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[],{"intervention":4330,"totalTrials":128,"cells":4341},{"EARLY_PHASE1":4342,"PHASE1":4344,"PHASE2":4350,"PHASE3":4352,"PHASE4":4354,"NA":4356},{"trials":4343,"activeCount":99},[],{"trials":4345,"activeCount":99},[4346],{"nctId":4321,"briefTitle":4322,"status":1120,"phases":4347,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":99,"conditions":4348,"interventions":4349},[87],[4327,2390,4328],[4314,4330,4331],{"trials":4351,"activeCount":99},[],{"trials":4353,"activeCount":99},[],{"trials":4355,"activeCount":99},[],{"trials":4357,"activeCount":99},[],{"intervention":4331,"totalTrials":128,"cells":4359},{"EARLY_PHASE1":4360,"PHASE1":4362,"PHASE2":4368,"PHASE3":4370,"PHASE4":4372,"NA":4374},{"trials":4361,"activeCount":99},[],{"trials":4363,"activeCount":99},[4364],{"nctId":4321,"briefTitle":4322,"status":1120,"phases":4365,"primaryCompletion":4324,"completion":4324,"start":4325,"enrollment":99,"conditions":4366,"interventions":4367},[87],[4327,2390,4328],[4314,4330,4331],{"trials":4369,"activeCount":99},[],{"trials":4371,"activeCount":99},[],{"trials":4373,"activeCount":99},[],{"trials":4375,"activeCount":99},[],{"intervention":501,"totalTrials":128,"cells":4377},{"EARLY_PHASE1":4378,"PHASE1":4380,"PHASE2":4386,"PHASE3":4388,"PHASE4":4390,"NA":4392},{"trials":4379,"activeCount":99},[],{"trials":4381,"activeCount":99},[4382],{"nctId":493,"briefTitle":494,"status":147,"phases":4383,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":4384,"interventions":4385},[87],[372],[337,501,360],{"trials":4387,"activeCount":99},[],{"trials":4389,"activeCount":99},[],{"trials":4391,"activeCount":99},[],{"trials":4393,"activeCount":99},[],{"intervention":4167,"totalTrials":128,"cells":4395},{"EARLY_PHASE1":4396,"PHASE1":4398,"PHASE2":4404,"PHASE3":4406,"PHASE4":4408,"NA":4410},{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[4400],{"nctId":4160,"briefTitle":4161,"status":147,"phases":4401,"primaryCompletion":2126,"completion":2126,"start":4163,"enrollment":774,"conditions":4402,"interventions":4403},[87],[4165],[4153,4167,4168],{"trials":4405,"activeCount":99},[],{"trials":4407,"activeCount":99},[],{"trials":4409,"activeCount":99},[],{"trials":4411,"activeCount":99},[],{"intervention":4168,"totalTrials":128,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4422,"PHASE3":4424,"PHASE4":4426,"NA":4428},{"trials":4415,"activeCount":99},[],{"trials":4417,"activeCount":99},[4418],{"nctId":4160,"briefTitle":4161,"status":147,"phases":4419,"primaryCompletion":2126,"completion":2126,"start":4163,"enrollment":774,"conditions":4420,"interventions":4421},[87],[4165],[4153,4167,4168],{"trials":4423,"activeCount":99},[],{"trials":4425,"activeCount":99},[],{"trials":4427,"activeCount":99},[],{"trials":4429,"activeCount":99},[],{"intervention":4204,"totalTrials":128,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4440,"PHASE3":4442,"PHASE4":4444,"NA":4446},{"trials":4433,"activeCount":99},[],{"trials":4435,"activeCount":99},[4436],{"nctId":4197,"briefTitle":4198,"status":366,"phases":4437,"primaryCompletion":4200,"start":4201,"enrollment":528,"conditions":4438,"interventions":4439},[87],[375,376],[3271,4204,4205],{"trials":4441,"activeCount":99},[],{"trials":4443,"activeCount":99},[],{"trials":4445,"activeCount":99},[],{"trials":4447,"activeCount":99},[],{"intervention":4205,"totalTrials":128,"cells":4449},{"EARLY_PHASE1":4450,"PHASE1":4452,"PHASE2":4458,"PHASE3":4460,"PHASE4":4462,"NA":4464},{"trials":4451,"activeCount":99},[],{"trials":4453,"activeCount":99},[4454],{"nctId":4197,"briefTitle":4198,"status":366,"phases":4455,"primaryCompletion":4200,"start":4201,"enrollment":528,"conditions":4456,"interventions":4457},[87],[375,376],[3271,4204,4205],{"trials":4459,"activeCount":99},[],{"trials":4461,"activeCount":99},[],{"trials":4463,"activeCount":99},[],{"trials":4465,"activeCount":99},[],{"intervention":3272,"totalTrials":128,"cells":4467},{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4476,"PHASE3":4478,"PHASE4":4480,"NA":4482},{"trials":4469,"activeCount":99},[],{"trials":4471,"activeCount":99},[4472],{"nctId":3265,"briefTitle":3266,"status":366,"phases":4473,"start":3268,"conditions":4474,"interventions":4475},[87],[373],[3271,3272,382],{"trials":4477,"activeCount":99},[],{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[],{"intervention":4485,"totalTrials":128,"cells":4486},"cytomegalovirus IE-1-specific cytotoxic T lymphocytes",{"EARLY_PHASE1":4487,"PHASE1":4489,"PHASE2":4502,"PHASE3":4504,"PHASE4":4506,"NA":4508},{"trials":4488,"activeCount":99},[],{"trials":4490,"activeCount":99},[4491],{"nctId":4492,"briefTitle":4493,"status":366,"phases":4494,"primaryCompletion":4495,"start":2617,"enrollment":15,"conditions":4496,"interventions":4498},"NCT00769613","Emergency Use of Donor Lymphocytes in Treating Patients Who Have Undergone Donor Stem Cell Transplant and Have Cytomegalovirus Infections",[87],"2014-08",[4497],"Cancer",[4485,4499,4500,4501],"cytomegalovirus pp65-specific cytotoxic T lymphocytes","therapeutic allogeneic lymphocytes","polymerase chain reaction",{"trials":4503,"activeCount":99},[],{"trials":4505,"activeCount":99},[],{"trials":4507,"activeCount":99},[],{"trials":4509,"activeCount":99},[],{"intervention":4499,"totalTrials":128,"cells":4511},{"EARLY_PHASE1":4512,"PHASE1":4514,"PHASE2":4520,"PHASE3":4522,"PHASE4":4524,"NA":4526},{"trials":4513,"activeCount":99},[],{"trials":4515,"activeCount":99},[4516],{"nctId":4492,"briefTitle":4493,"status":366,"phases":4517,"primaryCompletion":4495,"start":2617,"enrollment":15,"conditions":4518,"interventions":4519},[87],[4497],[4485,4499,4500,4501],{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[],{"trials":4527,"activeCount":99},[],{"intervention":4500,"totalTrials":128,"cells":4529},{"EARLY_PHASE1":4530,"PHASE1":4532,"PHASE2":4538,"PHASE3":4540,"PHASE4":4542,"NA":4544},{"trials":4531,"activeCount":99},[],{"trials":4533,"activeCount":99},[4534],{"nctId":4492,"briefTitle":4493,"status":366,"phases":4535,"primaryCompletion":4495,"start":2617,"enrollment":15,"conditions":4536,"interventions":4537},[87],[4497],[4485,4499,4500,4501],{"trials":4539,"activeCount":99},[],{"trials":4541,"activeCount":99},[],{"trials":4543,"activeCount":99},[],{"trials":4545,"activeCount":99},[],{"intervention":4501,"totalTrials":128,"cells":4547},{"EARLY_PHASE1":4548,"PHASE1":4550,"PHASE2":4556,"PHASE3":4558,"PHASE4":4560,"NA":4562},{"trials":4549,"activeCount":99},[],{"trials":4551,"activeCount":99},[4552],{"nctId":4492,"briefTitle":4493,"status":366,"phases":4553,"primaryCompletion":4495,"start":2617,"enrollment":15,"conditions":4554,"interventions":4555},[87],[4497],[4485,4499,4500,4501],{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[],{"trials":4561,"activeCount":99},[],{"trials":4563,"activeCount":99},[],{"intervention":4565,"totalTrials":128,"cells":4566},"Vorinostat, Bevacizumab, Carboplatin, Paclitaxel",{"EARLY_PHASE1":4567,"PHASE1":4569,"PHASE2":4579,"PHASE3":4581,"PHASE4":4583,"NA":4585},{"trials":4568,"activeCount":99},[],{"trials":4570,"activeCount":99},[4571],{"nctId":4572,"briefTitle":4573,"status":147,"phases":4574,"primaryCompletion":1831,"completion":2987,"start":4575,"enrollment":306,"conditions":4576,"interventions":4578},"NCT00702572","Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer",[87],"2008-04",[4577],"Non-small Cell Lung Cancer",[4565,4565],{"trials":4580,"activeCount":99},[],{"trials":4582,"activeCount":99},[],{"trials":4584,"activeCount":99},[],{"trials":4586,"activeCount":99},[],{"intervention":4588,"totalTrials":128,"cells":4589},"oral zinc and vitamin C supplements",{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4603,"PHASE3":4605,"PHASE4":4607,"NA":4609},{"trials":4591,"activeCount":99},[],{"trials":4593,"activeCount":99},[4594],{"nctId":4595,"briefTitle":4596,"status":147,"phases":4597,"primaryCompletion":3665,"completion":2056,"start":2092,"enrollment":4598,"conditions":4599,"interventions":4602},"NCT00325572","Evaluation and Treatment of Copper\u002FZinc Imbalance in Children With Autism",[87],89,[4600,4601],"Autism","Pervasive Developmental Disorder",[4588],{"trials":4604,"activeCount":99},[],{"trials":4606,"activeCount":99},[],{"trials":4608,"activeCount":99},[],{"trials":4610,"activeCount":99},[],{"intervention":4612,"totalTrials":128,"cells":4613},"AGN-Cogni.Q",{"EARLY_PHASE1":4614,"PHASE1":4616,"PHASE2":4626,"PHASE3":4628,"PHASE4":4630,"NA":4632},{"trials":4615,"activeCount":99},[],{"trials":4617,"activeCount":99},[4618],{"nctId":4619,"briefTitle":4620,"status":105,"phases":4621,"primaryCompletion":4622,"completion":4622,"start":4623,"enrollment":733,"conditions":4624,"interventions":4625},"NCT05375539","AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients",[87],"2025-02-15","2023-05-02",[639],[4612],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[],{"trials":4631,"activeCount":99},[],{"trials":4633,"activeCount":99},[],{"intervention":4635,"totalTrials":128,"cells":4636},"Capecitabine, Tarceva",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4649,"PHASE3":4651,"PHASE4":4653,"NA":4655},{"trials":4638,"activeCount":99},[],{"trials":4640,"activeCount":99},[4641],{"nctId":4642,"briefTitle":4643,"status":105,"phases":4644,"primaryCompletion":4645,"completion":4645,"start":4646,"enrollment":18,"conditions":4647,"interventions":4648},"NCT00565487","Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer",[87],"2014-08-05","2007-12",[3130],[4635],{"trials":4650,"activeCount":99},[],{"trials":4652,"activeCount":99},[],{"trials":4654,"activeCount":99},[],{"trials":4656,"activeCount":99},[],{"intervention":4658,"totalTrials":128,"cells":4659},"JVRS-100",{"EARLY_PHASE1":4660,"PHASE1":4662,"PHASE2":4673,"PHASE3":4675,"PHASE4":4677,"NA":4679},{"trials":4661,"activeCount":99},[],{"trials":4663,"activeCount":99},[4664],{"nctId":4665,"briefTitle":4666,"status":105,"phases":4667,"primaryCompletion":4668,"completion":4669,"start":4670,"enrollment":151,"conditions":4671,"interventions":4672},"NCT00860522","JVRS-100 for the Treatment of Patients With Relapsed or Refractory Leukemia",[87],"2014-10-31","2017-02-20","2009-03-01",[372],[4658,4658],{"trials":4674,"activeCount":99},[],{"trials":4676,"activeCount":99},[],{"trials":4678,"activeCount":99},[],{"trials":4680,"activeCount":99},[],{"intervention":3099,"totalTrials":128,"cells":4682},{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4691,"PHASE3":4693,"PHASE4":4695,"NA":4697},{"trials":4684,"activeCount":99},[],{"trials":4686,"activeCount":99},[4687],{"nctId":3093,"briefTitle":3094,"status":366,"phases":4688,"start":3096,"enrollment":15,"conditions":4689,"interventions":4690},[87],[377],[379,3099,3100,380,531,383,384],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[],{"trials":4696,"activeCount":99},[],{"trials":4698,"activeCount":99},[],{"intervention":3100,"totalTrials":128,"cells":4700},{"EARLY_PHASE1":4701,"PHASE1":4703,"PHASE2":4709,"PHASE3":4711,"PHASE4":4713,"NA":4715},{"trials":4702,"activeCount":99},[],{"trials":4704,"activeCount":99},[4705],{"nctId":3093,"briefTitle":3094,"status":366,"phases":4706,"start":3096,"enrollment":15,"conditions":4707,"interventions":4708},[87],[377],[379,3099,3100,380,531,383,384],{"trials":4710,"activeCount":99},[],{"trials":4712,"activeCount":99},[],{"trials":4714,"activeCount":99},[],{"trials":4716,"activeCount":99},[],{"intervention":4179,"totalTrials":128,"cells":4718},{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4727,"PHASE3":4729,"PHASE4":4731,"NA":4733},{"trials":4720,"activeCount":99},[],{"trials":4722,"activeCount":99},[4723],{"nctId":4170,"briefTitle":4171,"status":366,"phases":4724,"primaryCompletion":4173,"completion":4174,"start":4175,"enrollment":3640,"conditions":4725,"interventions":4726},[87],[4177],[4179,4180,4181],{"trials":4728,"activeCount":99},[],{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[],{"trials":4734,"activeCount":99},[],{"intervention":4181,"totalTrials":128,"cells":4736},{"EARLY_PHASE1":4737,"PHASE1":4739,"PHASE2":4745,"PHASE3":4747,"PHASE4":4749,"NA":4751},{"trials":4738,"activeCount":99},[],{"trials":4740,"activeCount":99},[4741],{"nctId":4170,"briefTitle":4171,"status":366,"phases":4742,"primaryCompletion":4173,"completion":4174,"start":4175,"enrollment":3640,"conditions":4743,"interventions":4744},[87],[4177],[4179,4180,4181],{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":99},[],{"trials":4750,"activeCount":99},[],{"trials":4752,"activeCount":99},[],{"intervention":4754,"totalTrials":128,"cells":4755},"PF-06412562",{"EARLY_PHASE1":4756,"PHASE1":4758,"PHASE2":4771,"PHASE3":4773,"PHASE4":4775,"NA":4777},{"trials":4757,"activeCount":99},[],{"trials":4759,"activeCount":99},[4760],{"nctId":4761,"briefTitle":4762,"status":105,"phases":4763,"primaryCompletion":4764,"completion":4765,"start":4766,"enrollment":24,"conditions":4767,"interventions":4769},"NCT03665454","PF 06412562 in Subjects With Advanced Stage Parkinson's Disease",[87],"2019-03-21","2019-04-21","2018-09-24",[4768],"Parkinson Disease",[4754,4770],"Standard of Care Placebo",{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[],{"trials":4776,"activeCount":99},[],{"trials":4778,"activeCount":99},[],{"intervention":4770,"totalTrials":128,"cells":4780},{"EARLY_PHASE1":4781,"PHASE1":4783,"PHASE2":4789,"PHASE3":4791,"PHASE4":4793,"NA":4795},{"trials":4782,"activeCount":99},[],{"trials":4784,"activeCount":99},[4785],{"nctId":4761,"briefTitle":4762,"status":105,"phases":4786,"primaryCompletion":4764,"completion":4765,"start":4766,"enrollment":24,"conditions":4787,"interventions":4788},[87],[4768],[4754,4770],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":99},[],{"trials":4794,"activeCount":99},[],{"trials":4796,"activeCount":99},[],{"intervention":3132,"totalTrials":128,"cells":4798},{"EARLY_PHASE1":4799,"PHASE1":4801,"PHASE2":4807,"PHASE3":4809,"PHASE4":4811,"NA":4813},{"trials":4800,"activeCount":99},[],{"trials":4802,"activeCount":99},[4803],{"nctId":3125,"briefTitle":3126,"status":147,"phases":4804,"primaryCompletion":2159,"completion":3128,"start":1485,"enrollment":747,"conditions":4805,"interventions":4806},[87],[3130],[3132,3118],{"trials":4808,"activeCount":99},[],{"trials":4810,"activeCount":99},[],{"trials":4812,"activeCount":99},[],{"trials":4814,"activeCount":99},[],{"intervention":4816,"totalTrials":128,"cells":4817},"Fluoxetine",{"EARLY_PHASE1":4818,"PHASE1":4829,"PHASE2":4831,"PHASE3":4833,"PHASE4":4835,"NA":4837},{"trials":4819,"activeCount":99},[4820],{"nctId":4821,"briefTitle":4822,"status":1120,"phases":4823,"primaryCompletion":4824,"completion":4825,"start":4826,"enrollment":99,"conditions":4827,"interventions":4828},"NCT04570449","Fluoxetine to Reduce Hospitalization From COVID-19 Infection (FloR COVID-19)",[86],"2021-11","2021-12","2020-11",[228],[4816],{"trials":4830,"activeCount":99},[],{"trials":4832,"activeCount":99},[],{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"trials":4838,"activeCount":99},[],{"intervention":4840,"totalTrials":128,"cells":4841},"Buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":4842,"PHASE1":4854,"PHASE2":4856,"PHASE3":4858,"PHASE4":4860,"NA":4862},{"trials":4843,"activeCount":99},[4844],{"nctId":4845,"briefTitle":4846,"status":1120,"phases":4847,"primaryCompletion":4848,"completion":4849,"start":4850,"enrollment":99,"conditions":4851,"interventions":4853},"NCT04794790","Buprenorphine Induction for Fentanyl Dependent Opioid Users",[86],"2024-02-22","2024-06-22","2022-05-09",[4852],"Opioid Dependence Fentanyl",[4840],{"trials":4855,"activeCount":99},[],{"trials":4857,"activeCount":99},[],{"trials":4859,"activeCount":99},[],{"trials":4861,"activeCount":99},[],{"trials":4863,"activeCount":99},[],{"intervention":4865,"totalTrials":128,"cells":4866},"Posaconazole Pill",{"EARLY_PHASE1":4867,"PHASE1":4880,"PHASE2":4882,"PHASE3":4884,"PHASE4":4886,"NA":4888},{"trials":4868,"activeCount":99},[4869],{"nctId":4870,"briefTitle":4871,"status":147,"phases":4872,"primaryCompletion":4873,"completion":4873,"start":4874,"enrollment":29,"conditions":4875,"interventions":4879},"NCT04825275","Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial",[86],"2024-11-06","2022-05-13",[4876,308,4877,4878],"Glioblastoma","Glioblastoma Multiforme of Brain","Glioblastoma Multiforme, Adult",[4865],{"trials":4881,"activeCount":99},[],{"trials":4883,"activeCount":99},[],{"trials":4885,"activeCount":99},[],{"trials":4887,"activeCount":99},[],{"trials":4889,"activeCount":99},[],{"intervention":4891,"totalTrials":128,"cells":4892},"Ketoconazole",{"EARLY_PHASE1":4893,"PHASE1":4903,"PHASE2":4905,"PHASE3":4907,"PHASE4":4909,"NA":4911},{"trials":4894,"activeCount":99},[4895],{"nctId":4896,"briefTitle":4897,"status":147,"phases":4898,"primaryCompletion":4899,"completion":4899,"start":4900,"enrollment":128,"conditions":4901,"interventions":4902},"NCT04869449","Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas",[86],"2022-05-12","2022-05-11",[4876,308,4877,4878],[4891],{"trials":4904,"activeCount":99},[],{"trials":4906,"activeCount":99},[],{"trials":4908,"activeCount":99},[],{"trials":4910,"activeCount":99},[],{"trials":4912,"activeCount":99},[],{"intervention":4914,"totalTrials":128,"cells":4915},"Lovaza",{"EARLY_PHASE1":4916,"PHASE1":4927,"PHASE2":4929,"PHASE3":4931,"PHASE4":4933,"NA":4935},{"trials":4917,"activeCount":99},[4918],{"nctId":4919,"briefTitle":4920,"status":1120,"phases":4921,"primaryCompletion":4922,"completion":4923,"start":4924,"enrollment":99,"conditions":4925,"interventions":4926},"NCT01784042","Dietary Energy Restriction and Omega-3 Fatty Acids on Mammary Tissue",[86],"2017-03","2018-03","2013-03",[17],[4914],{"trials":4928,"activeCount":99},[],{"trials":4930,"activeCount":99},[],{"trials":4932,"activeCount":99},[],{"trials":4934,"activeCount":99},[],{"trials":4936,"activeCount":99},[],{"intervention":4938,"totalTrials":128,"cells":4939},"Sevelamer Carbonate",{"EARLY_PHASE1":4940,"PHASE1":4950,"PHASE2":4952,"PHASE3":4954,"PHASE4":4956,"NA":4958},{"trials":4941,"activeCount":99},[4942],{"nctId":4943,"briefTitle":4944,"status":105,"phases":4945,"primaryCompletion":4946,"completion":4946,"start":496,"enrollment":124,"conditions":4947,"interventions":4949},"NCT01308242","Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease",[86],"2014-02-27",[4948],"Chronic Kidney Disease",[4938],{"trials":4951,"activeCount":99},[],{"trials":4953,"activeCount":99},[],{"trials":4955,"activeCount":99},[],{"trials":4957,"activeCount":99},[],{"trials":4959,"activeCount":99},[],{"intervention":778,"totalTrials":128,"cells":4961},{"EARLY_PHASE1":4962,"PHASE1":4968,"PHASE2":4970,"PHASE3":4972,"PHASE4":4974,"NA":4976},{"trials":4963,"activeCount":99},[4964],{"nctId":769,"briefTitle":770,"status":147,"phases":4965,"primaryCompletion":772,"completion":772,"start":773,"enrollment":774,"conditions":4966,"interventions":4967},[86],[776],[778,746],{"trials":4969,"activeCount":99},[],{"trials":4971,"activeCount":99},[],{"trials":4973,"activeCount":99},[],{"trials":4975,"activeCount":99},[],{"trials":4977,"activeCount":99},[],{"intervention":4979,"totalTrials":1058,"cells":4980},"Lidocaine",{"EARLY_PHASE1":4981,"PHASE1":4983,"PHASE2":4985,"PHASE3":4997,"PHASE4":4999,"NA":5005},{"trials":4982,"activeCount":99},[],{"trials":4984,"activeCount":99},[],{"trials":4986,"activeCount":99},[4987],{"nctId":4988,"briefTitle":4989,"status":147,"phases":4990,"primaryCompletion":1975,"completion":4991,"start":4992,"enrollment":774,"conditions":4993,"interventions":4996},"NCT03430531","Effectiveness of Sphenopalatine Ganglion Block for Post-Dural Puncture Headache",[88],"2022-03-11","2019-05-31",[4994,4995],"Post-Dural Puncture Headache","Sphenopalatine Ganglion Block",[4979],{"trials":4998,"activeCount":99},[],{"trials":5000,"activeCount":99},[5001],{"nctId":1717,"briefTitle":1718,"status":147,"phases":5002,"primaryCompletion":1720,"completion":1720,"start":1721,"enrollment":1235,"conditions":5003,"interventions":5004},[90],[1723],[1725,1704,1726],{"trials":5006,"activeCount":99},[5007],{"nctId":5008,"briefTitle":5009,"status":1120,"phases":5010,"primaryCompletion":3665,"completion":3665,"start":2617,"enrollment":99,"conditions":5011,"interventions":5013},"NCT00742846","Effects of Intra-articular Versus Subacromial Steroid Injections on Clinical Outcomes in Adhesive Capsulitis",[91],[5012],"Adhesive Capsulitis",[5014,5014,4979,4979],"Lidocaine + Kenalog",{"intervention":5016,"totalTrials":1058,"cells":5017},"Propofol",{"EARLY_PHASE1":5018,"PHASE1":5020,"PHASE2":5022,"PHASE3":5038,"PHASE4":5040,"NA":5042},{"trials":5019,"activeCount":99},[],{"trials":5021,"activeCount":99},[],{"trials":5023,"activeCount":99},[5024,5028],{"nctId":3782,"briefTitle":3783,"status":147,"phases":5025,"primaryCompletion":3785,"completion":3786,"start":3787,"enrollment":1009,"conditions":5026,"interventions":5027},[88],[3789],[3773,3791],{"nctId":5029,"briefTitle":5030,"status":105,"phases":5031,"primaryCompletion":5032,"completion":5032,"start":5033,"enrollment":5034,"conditions":5035,"interventions":5037},"NCT05759481","Prevention of Post-Operative Nausea and Vomiting With Propofol Infusion",[88],"2025-03-12","2024-02-01",68,[5036],"Post-operative Nausea and Vomiting",[5016],{"trials":5039,"activeCount":99},[],{"trials":5041,"activeCount":99},[],{"trials":5043,"activeCount":99},[5044],{"nctId":5045,"briefTitle":5046,"status":105,"phases":5047,"primaryCompletion":5048,"completion":5048,"start":5049,"enrollment":5050,"conditions":5051,"interventions":5053},"NCT02624050","Methohexital v Propofol as General Anesthetic in Patients on ACEIs or ARBs",[91],"2018-01-31","2016-08-01",51,[1878,5052],"Anesthesia",[5054,5016],"Methohexital",{"intervention":5056,"totalTrials":95,"cells":5057},"sugar pill",{"EARLY_PHASE1":5058,"PHASE1":5060,"PHASE2":5062,"PHASE3":5064,"PHASE4":5066,"NA":5068},{"trials":5059,"activeCount":99},[],{"trials":5061,"activeCount":99},[],{"trials":5063,"activeCount":99},[],{"trials":5065,"activeCount":99},[],{"trials":5067,"activeCount":99},[],{"trials":5069,"activeCount":99},[5070,5077],{"nctId":5071,"briefTitle":5072,"status":1120,"phases":5073,"primaryCompletion":1831,"enrollment":99,"conditions":5074,"interventions":5075},"NCT02388477","Trial of the Use of Doxycycline After Rotator Cuff Repair",[91],[1443],[5076,5056],"Doxycycline",{"nctId":5078,"briefTitle":5079,"status":147,"phases":5080,"primaryCompletion":3664,"completion":5081,"start":5082,"enrollment":747,"conditions":5083,"interventions":5085},"NCT01316042","Metformin for the Treatment of Premature Pubarche in Girls",[91],"2014-04","2011-05",[5084],"Premature Pubarche",[5056,5086],"Metformin, glucophage",{"intervention":5088,"totalTrials":95,"cells":5089},"Reduced Nicotine Content Cigarettes",{"EARLY_PHASE1":5090,"PHASE1":5092,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5091,"activeCount":99},[],{"trials":5093,"activeCount":99},[],{"trials":5095,"activeCount":99},[],{"trials":5097,"activeCount":99},[],{"trials":5099,"activeCount":99},[],{"trials":5101,"activeCount":99},[5102,5112],{"nctId":5103,"briefTitle":5104,"status":105,"phases":5105,"primaryCompletion":5106,"completion":5107,"start":2273,"enrollment":5108,"conditions":5109,"interventions":5110},"NCT01928758","Reduced Nicotine Cigarettes in Smokers With Mood and Anxiety Disorders",[91],"2018-01-11","2018-03-23",245,[26],[5088,5111],"Usual Nicotine Content Cigarettes",{"nctId":5113,"briefTitle":5114,"status":105,"phases":5115,"primaryCompletion":5116,"completion":5117,"start":5118,"enrollment":5119,"conditions":5120,"interventions":5121},"NCT01928719","Reduced Nicotine Content Cigarettes in Smokers of Lower Socioeconomic Status",[91],"2018-01-05","2018-02-23","2015-09-09",280,[26],[5088,5122],"Same Nicotine Content Cigarettes",{"intervention":5124,"totalTrials":95,"cells":5125},"Nicotine Film",{"EARLY_PHASE1":5126,"PHASE1":5128,"PHASE2":5130,"PHASE3":5143,"PHASE4":5145,"NA":5147},{"trials":5127,"activeCount":99},[],{"trials":5129,"activeCount":99},[],{"trials":5131,"activeCount":99},[5132],{"nctId":5133,"briefTitle":5134,"status":105,"phases":5135,"primaryCompletion":5136,"completion":5136,"start":5137,"enrollment":637,"conditions":5138,"interventions":5142},"NCT03674970","Effects of Random Nicotine Delivery on Smoking Cessation",[87,88],"2019-11-25","2019-03-12",[5139,5140,5141],"Smoking Cessation","Cigarette Smoking","Smoking (Tobacco) Addiction",[5124],{"trials":5144,"activeCount":99},[],{"trials":5146,"activeCount":99},[],{"trials":5148,"activeCount":99},[5149],{"nctId":5150,"briefTitle":5151,"status":105,"phases":5152,"primaryCompletion":5153,"completion":5153,"start":2273,"enrollment":1009,"conditions":5154,"interventions":5155},"NCT02239770","Pharmacokinetics of Nicotine Film in Smokers",[91],"2017-10",[5139],[5124],{"intervention":5157,"totalTrials":128,"cells":5158},"Raloxifene 60 Mg Oral",{"EARLY_PHASE1":5159,"PHASE1":5161,"PHASE2":5163,"PHASE3":5165,"PHASE4":5167,"NA":5169},{"trials":5160,"activeCount":99},[],{"trials":5162,"activeCount":99},[],{"trials":5164,"activeCount":99},[],{"trials":5166,"activeCount":99},[],{"trials":5168,"activeCount":99},[],{"trials":5170,"activeCount":99},[5171],{"nctId":5172,"briefTitle":5173,"status":105,"phases":5174,"primaryCompletion":1998,"completion":1998,"start":497,"enrollment":5175,"conditions":5176,"interventions":5177},"NCT00723398","Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention",[91],266,[17],[5157,5178,5179],"Raloxifene 30 Mg Oral","Lovaza 4gm & Raloxifene 30mg",{"intervention":5178,"totalTrials":128,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5190,"NA":5192},{"trials":5183,"activeCount":99},[],{"trials":5185,"activeCount":99},[],{"trials":5187,"activeCount":99},[],{"trials":5189,"activeCount":99},[],{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[5194],{"nctId":5172,"briefTitle":5173,"status":105,"phases":5195,"primaryCompletion":1998,"completion":1998,"start":497,"enrollment":5175,"conditions":5196,"interventions":5197},[91],[17],[5157,5178,5179],{"intervention":5179,"totalTrials":128,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5208,"NA":5210},{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":99},[],{"trials":5209,"activeCount":99},[],{"trials":5211,"activeCount":99},[5212],{"nctId":5172,"briefTitle":5173,"status":105,"phases":5213,"primaryCompletion":1998,"completion":1998,"start":497,"enrollment":5175,"conditions":5214,"interventions":5215},[91],[17],[5157,5178,5179],{"intervention":5014,"totalTrials":128,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5219,"activeCount":99},[],{"trials":5221,"activeCount":99},[],{"trials":5223,"activeCount":99},[],{"trials":5225,"activeCount":99},[],{"trials":5227,"activeCount":99},[],{"trials":5229,"activeCount":99},[5230],{"nctId":5008,"briefTitle":5009,"status":1120,"phases":5231,"primaryCompletion":3665,"completion":3665,"start":2617,"enrollment":99,"conditions":5232,"interventions":5233},[91],[5012],[5014,5014,4979,4979],{"intervention":5235,"totalTrials":128,"cells":5236},"Cyclin B1 Peptide",{"EARLY_PHASE1":5237,"PHASE1":5239,"PHASE2":5241,"PHASE3":5243,"PHASE4":5245,"NA":5247},{"trials":5238,"activeCount":99},[],{"trials":5240,"activeCount":99},[],{"trials":5242,"activeCount":99},[],{"trials":5244,"activeCount":99},[],{"trials":5246,"activeCount":99},[],{"trials":5248,"activeCount":99},[5249],{"nctId":5250,"briefTitle":5251,"status":1120,"phases":5252,"primaryCompletion":5253,"completion":5254,"start":107,"enrollment":99,"conditions":5255,"interventions":5256},"NCT01398124","Cyclin B1 Peptide-Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer",[91],"2014-12","2015-12",[4577],[5235],{"intervention":5258,"totalTrials":128,"cells":5259},"Gadopentetate Dimeglumine",{"EARLY_PHASE1":5260,"PHASE1":5262,"PHASE2":5264,"PHASE3":5266,"PHASE4":5268,"NA":5270},{"trials":5261,"activeCount":99},[],{"trials":5263,"activeCount":99},[],{"trials":5265,"activeCount":99},[],{"trials":5267,"activeCount":99},[],{"trials":5269,"activeCount":99},[],{"trials":5271,"activeCount":99},[5272],{"nctId":5273,"briefTitle":5274,"status":1120,"phases":5275,"primaryCompletion":109,"completion":109,"start":1873,"enrollment":99,"conditions":5276,"interventions":5277},"NCT01416740","A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation",[91],[1723],[5258],{"intervention":5076,"totalTrials":128,"cells":5279},{"EARLY_PHASE1":5280,"PHASE1":5282,"PHASE2":5284,"PHASE3":5286,"PHASE4":5288,"NA":5290},{"trials":5281,"activeCount":99},[],{"trials":5283,"activeCount":99},[],{"trials":5285,"activeCount":99},[],{"trials":5287,"activeCount":99},[],{"trials":5289,"activeCount":99},[],{"trials":5291,"activeCount":99},[5292],{"nctId":5071,"briefTitle":5072,"status":1120,"phases":5293,"primaryCompletion":1831,"enrollment":99,"conditions":5294,"interventions":5295},[91],[1443],[5076,5056],{"intervention":5297,"totalTrials":128,"cells":5298},"PAI Tool and Exercise Coaching",{"EARLY_PHASE1":5299,"PHASE1":5301,"PHASE2":5303,"PHASE3":5305,"PHASE4":5307,"NA":5309},{"trials":5300,"activeCount":99},[],{"trials":5302,"activeCount":99},[],{"trials":5304,"activeCount":99},[],{"trials":5306,"activeCount":99},[],{"trials":5308,"activeCount":99},[],{"trials":5310,"activeCount":99},[5311],{"nctId":5312,"briefTitle":5313,"status":1120,"phases":5314,"primaryCompletion":5315,"completion":5315,"start":5315,"enrollment":99,"conditions":5316,"interventions":5318},"NCT05156463","The PAI Trial for Breast and Colon Cancer Survivors",[91],"2022-04-12",[17,5317],"Colon Cancer",[5297],{"intervention":5320,"totalTrials":128,"cells":5321},"BenzaClin",{"EARLY_PHASE1":5322,"PHASE1":5324,"PHASE2":5326,"PHASE3":5328,"PHASE4":5330,"NA":5332},{"trials":5323,"activeCount":99},[],{"trials":5325,"activeCount":99},[],{"trials":5327,"activeCount":99},[],{"trials":5329,"activeCount":99},[],{"trials":5331,"activeCount":99},[],{"trials":5333,"activeCount":99},[5334],{"nctId":5335,"briefTitle":5336,"status":105,"phases":5337,"primaryCompletion":3812,"completion":3128,"start":5338,"enrollment":5339,"conditions":5340,"interventions":5342},"NCT01237821","Comparing OTC Acne Treatment to Prescription Regimen",[91],"2010-10",66,[5341],"Acne Vulgaris",[5320,5343],"Effaclar",{"intervention":5343,"totalTrials":128,"cells":5345},{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5350,"PHASE3":5352,"PHASE4":5354,"NA":5356},{"trials":5347,"activeCount":99},[],{"trials":5349,"activeCount":99},[],{"trials":5351,"activeCount":99},[],{"trials":5353,"activeCount":99},[],{"trials":5355,"activeCount":99},[],{"trials":5357,"activeCount":99},[5358],{"nctId":5335,"briefTitle":5336,"status":105,"phases":5359,"primaryCompletion":3812,"completion":3128,"start":5338,"enrollment":5339,"conditions":5360,"interventions":5361},[91],[5341],[5320,5343],{"intervention":5363,"totalTrials":128,"cells":5364},"Arm A: Everolimus",{"EARLY_PHASE1":5365,"PHASE1":5367,"PHASE2":5369,"PHASE3":5371,"PHASE4":5373,"NA":5375},{"trials":5366,"activeCount":99},[],{"trials":5368,"activeCount":99},[],{"trials":5370,"activeCount":99},[],{"trials":5372,"activeCount":99},[],{"trials":5374,"activeCount":99},[],{"trials":5376,"activeCount":99},[5377],{"nctId":5378,"briefTitle":5379,"status":105,"phases":5380,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":1009,"conditions":5383,"interventions":5386},"NCT01936519","Conversion to Everolimus From Calcineurin Inhibitor With Mycophenolic Acid: Impact on Long Term Renal Function in Liver Transplantation.",[91],"2019-07-31","2013-12-16",[5384,5385],"Immunosuppression","Renal Failure",[5363,5387],"Calcineurin Inhibitor",{"intervention":5387,"totalTrials":128,"cells":5389},{"EARLY_PHASE1":5390,"PHASE1":5392,"PHASE2":5394,"PHASE3":5396,"PHASE4":5398,"NA":5400},{"trials":5391,"activeCount":99},[],{"trials":5393,"activeCount":99},[],{"trials":5395,"activeCount":99},[],{"trials":5397,"activeCount":99},[],{"trials":5399,"activeCount":99},[],{"trials":5401,"activeCount":99},[5402],{"nctId":5378,"briefTitle":5379,"status":105,"phases":5403,"primaryCompletion":5381,"completion":5381,"start":5382,"enrollment":1009,"conditions":5404,"interventions":5405},[91],[5384,5385],[5363,5387],{"intervention":5407,"totalTrials":128,"cells":5408},"Prazosin",{"EARLY_PHASE1":5409,"PHASE1":5411,"PHASE2":5413,"PHASE3":5415,"PHASE4":5417,"NA":5419},{"trials":5410,"activeCount":99},[],{"trials":5412,"activeCount":99},[],{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[],{"trials":5418,"activeCount":99},[],{"trials":5420,"activeCount":99},[5421],{"nctId":5422,"briefTitle":5423,"status":105,"phases":5424,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":21,"conditions":5427,"interventions":5430},"NCT02382848","Effectiveness of Prazosin in Bulimic Patients Experiencing Nightmares Due to PTSD",[91],"2018-03-09","2015-07",[5428,5429],"Stress Disorders, Post-Traumatic","Bulimia Nervosa",[5407,5407],{"intervention":5432,"totalTrials":128,"cells":5433},"Low Dose Contrast (Omnipaque) 40mL",{"EARLY_PHASE1":5434,"PHASE1":5436,"PHASE2":5438,"PHASE3":5440,"PHASE4":5442,"NA":5444},{"trials":5435,"activeCount":99},[],{"trials":5437,"activeCount":99},[],{"trials":5439,"activeCount":99},[],{"trials":5441,"activeCount":99},[],{"trials":5443,"activeCount":99},[],{"trials":5445,"activeCount":99},[5446],{"nctId":5447,"briefTitle":5448,"status":105,"phases":5449,"primaryCompletion":5450,"completion":5451,"start":1610,"enrollment":1260,"conditions":5452,"interventions":5456},"NCT02669784","Computed Tomography Arteriograms (CTA) Volume Dose Reduction Study",[91],"2017-05","2018-11",[5453,5454,5455],"Aortic Aneurysm","Contrast Induced Nephropathy","Aortic and Arterial Anomalies",[5432,5457],"Low Dose Contrast (Omnipaque) 50 mL",{"intervention":5457,"totalTrials":128,"cells":5459},{"EARLY_PHASE1":5460,"PHASE1":5462,"PHASE2":5464,"PHASE3":5466,"PHASE4":5468,"NA":5470},{"trials":5461,"activeCount":99},[],{"trials":5463,"activeCount":99},[],{"trials":5465,"activeCount":99},[],{"trials":5467,"activeCount":99},[],{"trials":5469,"activeCount":99},[],{"trials":5471,"activeCount":99},[5472],{"nctId":5447,"briefTitle":5448,"status":105,"phases":5473,"primaryCompletion":5450,"completion":5451,"start":1610,"enrollment":1260,"conditions":5474,"interventions":5475},[91],[5453,5454,5455],[5432,5457],{"intervention":5477,"totalTrials":128,"cells":5478},"carboxymethylcellulose sodium",{"EARLY_PHASE1":5479,"PHASE1":5481,"PHASE2":5483,"PHASE3":5485,"PHASE4":5487,"NA":5489},{"trials":5480,"activeCount":99},[],{"trials":5482,"activeCount":99},[],{"trials":5484,"activeCount":99},[],{"trials":5486,"activeCount":99},[],{"trials":5488,"activeCount":99},[],{"trials":5490,"activeCount":99},[5491],{"nctId":5492,"briefTitle":5493,"status":1120,"phases":5494,"primaryCompletion":5495,"completion":5495,"start":5496,"enrollment":99,"conditions":5497,"interventions":5499},"NCT02395952","Healing of Persistent Epithelial Defects",[91],"2018-02","2015-03",[5498],"Cornea",[5477],{"intervention":5501,"totalTrials":128,"cells":5502},"Very low nicotine content cigarettes",{"EARLY_PHASE1":5503,"PHASE1":5505,"PHASE2":5507,"PHASE3":5509,"PHASE4":5511,"NA":5513},{"trials":5504,"activeCount":99},[],{"trials":5506,"activeCount":99},[],{"trials":5508,"activeCount":99},[],{"trials":5510,"activeCount":99},[],{"trials":5512,"activeCount":99},[],{"trials":5514,"activeCount":99},[5515],{"nctId":5516,"briefTitle":5517,"status":105,"phases":5518,"primaryCompletion":5519,"completion":5519,"start":5520,"enrollment":1260,"conditions":5521,"interventions":5522},"NCT03612960","Measuring Neuroadaptations in Response to Very Low Nicotine Content Cigarettes",[91],"2023-06-23","2020-02-20",[26],[5501,5523],"Normal nicotine content cigarettes",{"intervention":5523,"totalTrials":128,"cells":5525},{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5530,"PHASE3":5532,"PHASE4":5534,"NA":5536},{"trials":5527,"activeCount":99},[],{"trials":5529,"activeCount":99},[],{"trials":5531,"activeCount":99},[],{"trials":5533,"activeCount":99},[],{"trials":5535,"activeCount":99},[],{"trials":5537,"activeCount":99},[5538],{"nctId":5516,"briefTitle":5517,"status":105,"phases":5539,"primaryCompletion":5519,"completion":5519,"start":5520,"enrollment":1260,"conditions":5540,"interventions":5541},[91],[26],[5501,5523],{"intervention":5543,"totalTrials":128,"cells":5544},"Ramelteon and Escitalopram",{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5549,"PHASE3":5551,"PHASE4":5553,"NA":5555},{"trials":5546,"activeCount":99},[],{"trials":5548,"activeCount":99},[],{"trials":5550,"activeCount":99},[],{"trials":5552,"activeCount":99},[],{"trials":5554,"activeCount":99},[],{"trials":5556,"activeCount":99},[5557],{"nctId":5558,"briefTitle":5559,"status":147,"phases":5560,"primaryCompletion":2616,"completion":2616,"start":2617,"enrollment":151,"conditions":5561,"interventions":5563},"NCT00746239","Ramelteon for Sleep Initiation Insomnia in Individuals With Panic Disorder Who Are Also on Escitalopram for Anxiety",[91],[5562,989],"Panic Disorder",[5543],{"intervention":5565,"totalTrials":128,"cells":5566},"RRR-alpha-tocopherol 1,000 IU\u002FmL",{"EARLY_PHASE1":5567,"PHASE1":5569,"PHASE2":5571,"PHASE3":5573,"PHASE4":5575,"NA":5577},{"trials":5568,"activeCount":99},[],{"trials":5570,"activeCount":99},[],{"trials":5572,"activeCount":99},[],{"trials":5574,"activeCount":99},[],{"trials":5576,"activeCount":99},[],{"trials":5578,"activeCount":99},[5579],{"nctId":5580,"briefTitle":5581,"status":147,"phases":5582,"primaryCompletion":5583,"completion":5583,"start":5584,"enrollment":528,"conditions":5585,"interventions":5586},"NCT00281307","Treatment of Rhinitis With Intranasal Vitamin E",[91],"2007-09-01","2005-12-07",[2642],[5565],{"intervention":5588,"totalTrials":128,"cells":5589},"LMX4",{"EARLY_PHASE1":5590,"PHASE1":5592,"PHASE2":5594,"PHASE3":5596,"PHASE4":5598,"NA":5600},{"trials":5591,"activeCount":99},[],{"trials":5593,"activeCount":99},[],{"trials":5595,"activeCount":99},[],{"trials":5597,"activeCount":99},[],{"trials":5599,"activeCount":99},[],{"trials":5601,"activeCount":99},[5602],{"nctId":5603,"briefTitle":5604,"status":1120,"phases":5605,"primaryCompletion":5606,"completion":3664,"start":2360,"enrollment":99,"conditions":5607,"interventions":5608},"NCT01842373","Comparison Study on Topical Anesthetic Agents (LMX4 and BLT) Prior to Fractional Skin Resurfacing",[91],"2013-09",[23],[5588,5609],"BLT",{"intervention":5609,"totalTrials":128,"cells":5611},{"EARLY_PHASE1":5612,"PHASE1":5614,"PHASE2":5616,"PHASE3":5618,"PHASE4":5620,"NA":5622},{"trials":5613,"activeCount":99},[],{"trials":5615,"activeCount":99},[],{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[],{"trials":5621,"activeCount":99},[],{"trials":5623,"activeCount":99},[5624],{"nctId":5603,"briefTitle":5604,"status":1120,"phases":5625,"primaryCompletion":5606,"completion":3664,"start":2360,"enrollment":99,"conditions":5626,"interventions":5627},[91],[23],[5588,5609],{"intervention":5629,"totalTrials":128,"cells":5630},"Olanzapine 10 mg po qhs for 3 days",{"EARLY_PHASE1":5631,"PHASE1":5633,"PHASE2":5635,"PHASE3":5637,"PHASE4":5639,"NA":5641},{"trials":5632,"activeCount":99},[],{"trials":5634,"activeCount":99},[],{"trials":5636,"activeCount":99},[],{"trials":5638,"activeCount":99},[],{"trials":5640,"activeCount":99},[],{"trials":5642,"activeCount":99},[5643],{"nctId":5644,"briefTitle":5645,"status":105,"phases":5646,"primaryCompletion":3665,"completion":5082,"start":2617,"enrollment":18,"conditions":5647,"interventions":5648},"NCT00741026","A Crossover Study of the Acute Effects of Olanzapine in Healthy Volunteers",[91],[3712,1445],[5629],{"intervention":5111,"totalTrials":128,"cells":5650},{"EARLY_PHASE1":5651,"PHASE1":5653,"PHASE2":5655,"PHASE3":5657,"PHASE4":5659,"NA":5661},{"trials":5652,"activeCount":99},[],{"trials":5654,"activeCount":99},[],{"trials":5656,"activeCount":99},[],{"trials":5658,"activeCount":99},[],{"trials":5660,"activeCount":99},[],{"trials":5662,"activeCount":99},[5663],{"nctId":5103,"briefTitle":5104,"status":105,"phases":5664,"primaryCompletion":5106,"completion":5107,"start":2273,"enrollment":5108,"conditions":5665,"interventions":5666},[91],[26],[5088,5111],{"intervention":5054,"totalTrials":128,"cells":5668},{"EARLY_PHASE1":5669,"PHASE1":5671,"PHASE2":5673,"PHASE3":5675,"PHASE4":5677,"NA":5679},{"trials":5670,"activeCount":99},[],{"trials":5672,"activeCount":99},[],{"trials":5674,"activeCount":99},[],{"trials":5676,"activeCount":99},[],{"trials":5678,"activeCount":99},[],{"trials":5680,"activeCount":99},[5681],{"nctId":5045,"briefTitle":5046,"status":105,"phases":5682,"primaryCompletion":5048,"completion":5048,"start":5049,"enrollment":5050,"conditions":5683,"interventions":5684},[91],[1878,5052],[5054,5016],{"intervention":5686,"totalTrials":128,"cells":5687},"fecal microbiota transplant",{"EARLY_PHASE1":5688,"PHASE1":5690,"PHASE2":5692,"PHASE3":5694,"PHASE4":5696,"NA":5698},{"trials":5689,"activeCount":99},[],{"trials":5691,"activeCount":99},[],{"trials":5693,"activeCount":99},[],{"trials":5695,"activeCount":99},[],{"trials":5697,"activeCount":99},[],{"trials":5699,"activeCount":99},[5700],{"nctId":5701,"briefTitle":5702,"status":1120,"phases":5703,"primaryCompletion":5704,"completion":5704,"start":5705,"enrollment":99,"conditions":5706,"interventions":5708},"NCT02968511","EGESTA - Emergent GI Therapy for Severe, Complicated CDI Using Fecal Microbiota Transplant",[91],"2017-11-14","2016-09-15",[5707],"C.Difficile Colitis",[5686],{"intervention":5710,"totalTrials":128,"cells":5711},"Intrathecal local anesthesia",{"EARLY_PHASE1":5712,"PHASE1":5714,"PHASE2":5716,"PHASE3":5718,"PHASE4":5720,"NA":5722},{"trials":5713,"activeCount":99},[],{"trials":5715,"activeCount":99},[],{"trials":5717,"activeCount":99},[],{"trials":5719,"activeCount":99},[],{"trials":5721,"activeCount":99},[],{"trials":5723,"activeCount":99},[5724],{"nctId":5725,"briefTitle":5726,"status":105,"phases":5727,"primaryCompletion":5728,"completion":5728,"start":5729,"enrollment":528,"conditions":5730,"interventions":5734},"NCT05650008","Effects of Intrathecal Local Anesthetics on Left Ventricular Global Longitudinal Strain",[],"2023-10-10","2023-02-01",[5731,5732,5733],"Left Ventricular Dysfunction","Spinal Anesthetics Causing Adverse Effects in Therapeutic Use","Global Cardiac Wall Motion Dysfunction",[5710],{"intervention":5736,"totalTrials":128,"cells":5737},"Indocyanine green",{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5742,"PHASE3":5744,"PHASE4":5746,"NA":5748},{"trials":5739,"activeCount":99},[],{"trials":5741,"activeCount":99},[],{"trials":5743,"activeCount":99},[],{"trials":5745,"activeCount":99},[],{"trials":5747,"activeCount":99},[],{"trials":5749,"activeCount":99},[5750],{"nctId":5751,"briefTitle":5752,"status":105,"phases":5753,"primaryCompletion":1028,"completion":1610,"start":2359,"enrollment":4598,"conditions":5754,"interventions":5757},"NCT02057393","Infrared Lymphangiography as a Method of Sentinel Node Identification",[91],[5755,5756],"Melanoma","Sentinel Node",[5736,5758,5759],"Technetium99","Methylene blue",{"intervention":5758,"totalTrials":128,"cells":5761},{"EARLY_PHASE1":5762,"PHASE1":5764,"PHASE2":5766,"PHASE3":5768,"PHASE4":5770,"NA":5772},{"trials":5763,"activeCount":99},[],{"trials":5765,"activeCount":99},[],{"trials":5767,"activeCount":99},[],{"trials":5769,"activeCount":99},[],{"trials":5771,"activeCount":99},[],{"trials":5773,"activeCount":99},[5774],{"nctId":5751,"briefTitle":5752,"status":105,"phases":5775,"primaryCompletion":1028,"completion":1610,"start":2359,"enrollment":4598,"conditions":5776,"interventions":5777},[91],[5755,5756],[5736,5758,5759],{"intervention":5759,"totalTrials":128,"cells":5779},{"EARLY_PHASE1":5780,"PHASE1":5782,"PHASE2":5784,"PHASE3":5786,"PHASE4":5788,"NA":5790},{"trials":5781,"activeCount":99},[],{"trials":5783,"activeCount":99},[],{"trials":5785,"activeCount":99},[],{"trials":5787,"activeCount":99},[],{"trials":5789,"activeCount":99},[],{"trials":5791,"activeCount":99},[5792],{"nctId":5751,"briefTitle":5752,"status":105,"phases":5793,"primaryCompletion":1028,"completion":1610,"start":2359,"enrollment":4598,"conditions":5794,"interventions":5795},[91],[5755,5756],[5736,5758,5759],{"intervention":5797,"totalTrials":128,"cells":5798},"Aromastick",{"EARLY_PHASE1":5799,"PHASE1":5801,"PHASE2":5803,"PHASE3":5805,"PHASE4":5807,"NA":5809},{"trials":5800,"activeCount":99},[],{"trials":5802,"activeCount":99},[],{"trials":5804,"activeCount":99},[],{"trials":5806,"activeCount":99},[],{"trials":5808,"activeCount":99},[],{"trials":5810,"activeCount":99},[5811],{"nctId":5812,"briefTitle":5813,"status":105,"phases":5814,"primaryCompletion":5815,"completion":5815,"start":5816,"enrollment":774,"conditions":5817,"interventions":5820},"NCT04396444","Lavender Aromasticks for Pain Control",[91],"2021-10-31","2020-08-01",[5818,5819],"Pain Perception","Patient Satisfaction",[5797],{"intervention":5822,"totalTrials":128,"cells":5823},"HPV 9-valent Vaccine, Recombinant",{"EARLY_PHASE1":5824,"PHASE1":5826,"PHASE2":5828,"PHASE3":5830,"PHASE4":5832,"NA":5834},{"trials":5825,"activeCount":99},[],{"trials":5827,"activeCount":99},[],{"trials":5829,"activeCount":99},[],{"trials":5831,"activeCount":99},[],{"trials":5833,"activeCount":99},[],{"trials":5835,"activeCount":99},[5836],{"nctId":5837,"briefTitle":5838,"status":1120,"phases":5839,"primaryCompletion":5840,"completion":5841,"start":5842,"enrollment":99,"conditions":5843,"interventions":5845},"NCT04430907","HPV Vaccine in Postpartum Women",[],"2022-09","2023-09","2021-09",[5844],"HPV Infection",[5822],{"intervention":5847,"totalTrials":128,"cells":5848},"fluticasone",{"EARLY_PHASE1":5849,"PHASE1":5851,"PHASE2":5853,"PHASE3":5855,"PHASE4":5857,"NA":5859},{"trials":5850,"activeCount":99},[],{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"trials":5858,"activeCount":99},[],{"trials":5860,"activeCount":99},[5861],{"nctId":5862,"briefTitle":5863,"status":105,"phases":5864,"primaryCompletion":2231,"completion":2231,"start":5865,"enrollment":5866,"conditions":5867,"interventions":5869},"NCT01537133","Airway Microbiome in Asthma: Relationships to Asthma Phenotype and Inhaled Corticosteroid Treatment",[91],"2012-10",84,[14,5868],"Atopy",[5847],{"intervention":5086,"totalTrials":128,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5873,"activeCount":99},[],{"trials":5875,"activeCount":99},[],{"trials":5877,"activeCount":99},[],{"trials":5879,"activeCount":99},[],{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[5884],{"nctId":5078,"briefTitle":5079,"status":147,"phases":5885,"primaryCompletion":3664,"completion":5081,"start":5082,"enrollment":747,"conditions":5886,"interventions":5887},[91],[5084],[5056,5086],{"intervention":5889,"totalTrials":128,"cells":5890},"Ketamine",{"EARLY_PHASE1":5891,"PHASE1":5893,"PHASE2":5895,"PHASE3":5897,"PHASE4":5899,"NA":5901},{"trials":5892,"activeCount":99},[],{"trials":5894,"activeCount":99},[],{"trials":5896,"activeCount":99},[],{"trials":5898,"activeCount":99},[],{"trials":5900,"activeCount":99},[],{"trials":5902,"activeCount":99},[5903],{"nctId":5904,"briefTitle":5905,"status":105,"phases":5906,"primaryCompletion":5907,"completion":5907,"start":5908,"enrollment":5909,"conditions":5910,"interventions":5911},"NCT02334059","Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery",[91],"2019-03-13","2015-11",108,[20],[5889,5912],"Ketamine plus magnesium",{"intervention":5912,"totalTrials":128,"cells":5914},{"EARLY_PHASE1":5915,"PHASE1":5917,"PHASE2":5919,"PHASE3":5921,"PHASE4":5923,"NA":5925},{"trials":5916,"activeCount":99},[],{"trials":5918,"activeCount":99},[],{"trials":5920,"activeCount":99},[],{"trials":5922,"activeCount":99},[],{"trials":5924,"activeCount":99},[],{"trials":5926,"activeCount":99},[5927],{"nctId":5904,"briefTitle":5905,"status":105,"phases":5928,"primaryCompletion":5907,"completion":5907,"start":5908,"enrollment":5909,"conditions":5929,"interventions":5930},[91],[20],[5889,5912],{"intervention":5122,"totalTrials":128,"cells":5932},{"EARLY_PHASE1":5933,"PHASE1":5935,"PHASE2":5937,"PHASE3":5939,"PHASE4":5941,"NA":5943},{"trials":5934,"activeCount":99},[],{"trials":5936,"activeCount":99},[],{"trials":5938,"activeCount":99},[],{"trials":5940,"activeCount":99},[],{"trials":5942,"activeCount":99},[],{"trials":5944,"activeCount":99},[5945],{"nctId":5113,"briefTitle":5114,"status":105,"phases":5946,"primaryCompletion":5116,"completion":5117,"start":5118,"enrollment":5119,"conditions":5947,"interventions":5948},[91],[26],[5088,5122],{"intervention":5950,"totalTrials":128,"cells":5951},"Glutathione supplementation",{"EARLY_PHASE1":5952,"PHASE1":5954,"PHASE2":5956,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5953,"activeCount":99},[],{"trials":5955,"activeCount":99},[],{"trials":5957,"activeCount":99},[],{"trials":5959,"activeCount":99},[],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[5964],{"nctId":5965,"briefTitle":5966,"status":105,"phases":5967,"primaryCompletion":5968,"completion":5969,"start":1874,"enrollment":5970,"conditions":5971,"interventions":5973},"NCT01044277","Oral Glutathione Supplementation on the Levels of Blood Glutathione",[91],"2011-09","2014-10",61,[5972],"Healthy Adults",[5950,5974],"Gluthathione peroxidases",{"intervention":5974,"totalTrials":128,"cells":5976},{"EARLY_PHASE1":5977,"PHASE1":5979,"PHASE2":5981,"PHASE3":5983,"PHASE4":5985,"NA":5987},{"trials":5978,"activeCount":99},[],{"trials":5980,"activeCount":99},[],{"trials":5982,"activeCount":99},[],{"trials":5984,"activeCount":99},[],{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[5989],{"nctId":5965,"briefTitle":5966,"status":105,"phases":5990,"primaryCompletion":5968,"completion":5969,"start":1874,"enrollment":5970,"conditions":5991,"interventions":5992},[91],[5972],[5950,5974],{"intervention":5994,"totalTrials":128,"cells":5995},"Oral Omega-3-acid ethyl esters",{"EARLY_PHASE1":5996,"PHASE1":5998,"PHASE2":6000,"PHASE3":6002,"PHASE4":6004,"NA":6006},{"trials":5997,"activeCount":99},[],{"trials":5999,"activeCount":99},[],{"trials":6001,"activeCount":99},[],{"trials":6003,"activeCount":99},[],{"trials":6005,"activeCount":99},[],{"trials":6007,"activeCount":99},[6008],{"nctId":6009,"briefTitle":6010,"status":105,"phases":6011,"primaryCompletion":4495,"completion":6012,"start":2616,"enrollment":3761,"conditions":6013,"interventions":6015},"NCT01107964","Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome",[91],"2015-06-15",[6014],"Dry Eye Syndrome",[5994]]